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Abstract
Multidrug resistant organisms (MDROs) pose a threat to healthcare facilities worldwide
due to global prevalence, limited treatment options, and high mortality rates. This thesis
acts as a proof-of-principle study for using whole-genome sequencing and associated clin-
ical metadata to provide actionable insights into MDRO infection prevention and control
practices. We focus our analysis on carbapenem-resistant Klebsiella pneumoniae (CRKP)
sequence type (ST) 258, an MDRO that is particularly prevalent in long-term acute care
hospitals (LTACHs) in the United States (US). Using a comprehensive set of 417 clinical
CRKP ST258 isolates collected over the course of a year in 21 US LTACHs, we investigate
regional transmission, predictors of infection, and evolution of antibiotic resistance. In ad-
dition, we develop three open-source R packages that implement methods developed and
applied here: regentrans for studying regional pathogen transmission, mikropml for per-
forming machine learning, and prewas for preprocessing data prior to bacterial genome-wide
association studies.
First, we reconstructed regional transmission pathways with genomic data and analyzed
this network in the context of patient transfer data and patient-level clinical data to identify
potential drivers of regional CRKP transmission. We found high regional CRKP burdens
in Los Angeles area LTACHs that were due to a small number of introductions with sub-
sequent proliferation occurring via within-facility transmission and patient transfers among
healthcare facilities.
As only a subset of colonized patients develop clinical infection, we next used machine
xiii
learning to determine whether patient characteristics and CRKP genetic background can
predict infection status. We found that patient and genomic features were predictive of
clinical CRKP infection to similar extents. Genomic predictors of infection included presence
of the ICEKp10 mobile genetic element carrying the yersiniabactin iron acquisition system
and disruption of the O-antigen biosynthetic gene kfoC in a CRKP ST258 sublineage (clade
IIB). Disrupted kfoC was associated with isolation from the respiratory tract, and subsequent
ICEKp10 acquisition was associated with increased virulence. These results highlight the
utility of machine learning to provide insight into patient clinical trajectories and ongoing
within-lineage pathogen adaptation.
Finally, we investigated the evolution of CRKP resistant to the antibiotic colistin, one of
the few remaining treatment options for this MDRO. Two large clusters of resistant strains
in clade IIB accounted for over half of the detected colistin resistance, in stark contrast to
the sporadic resistance events observed in other clades. Moreover, while resistant isolates
from other clades were less fit than susceptible non-revertant isolates, clade IIB resistant
isolates were more fit, underscoring the potential for continued regional spread of clade IIB
colistin resistant strains.
In summary, we identified an emerging CRKP sublineage that has spread across Los
Angeles area LTACHs and appears to have an increased affinity for the respiratory tract,
increased transmissibility, and a decreased fitness cost of colistin resistance. Future work
should continue to monitor this strain as increased prevalence could reduce the efficacy of
colistin as a treatment for CRKP in this region and possibly lead to exportation to other
regions. Additionally, these findings highlight the potential impact of incorporating genomic
epidemiology into regional infection prevention efforts to identify high-transmission facilities






Multidrug resistant organisms (MDROs) are a global public health threat due to rampant
spread, high levels of morbidity and mortality, and continued evolution to additional antibi-
otics [1]. Monitoring and surveillance of MDROs requires methods for analysis of transmis-
sion, adaptation to the healthcare environment, and evolution of antibiotic resistance. This
dissertation acts as a proof-of-principle study for how to integrate whole-genome sequences of
clinical isolates with corresponding patient metadata to investigate endemic, yet continually
evolving, public health threats. Specifically, we study transmission, infection, and antibiotic
resistance evolution of the nosocomial pathogen carbapenem resistant Klebsiella pneumo-
niae (CRKP). The bioinformatic framework and corresponding tools developed here can be
applied to investigate the transmission and evolution of other nosocomial pathogens.
1.2 CRKP history and population genomics
K. pneumoniae was first isolated from a patient with pneumonia in the late 1800s [2]. This
Gram-negative rod-shaped bacterium can colonize the gastrointestinal tract and cause pneu-
monia, urinary tract infections, and bacteremia, primarily in immunocompromised individ-
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uals in the healthcare setting [3]. In the past several decades, some K. pneumoniae have
acquired antibiotic resistance elements that make them very difficult to treat. Of particular
concern are CRKP, which are strains that have become resistant to carbapenems [4].
The majority of CRKP in the United States (US) harbor K. pneumoniae carbapenemase
(KPC), which confers resistance to carbapenems [5]. KPC was first discovered in a 1996 K.
pneumoniae isolate [6]. In 2003, outbreaks of CRKP occurred across New York healthcare
facilities, and by 2005 CRKP had spread to several other countries including Israel, Italy,
Colombia, the United Kingdom, and Sweden [7]. CRKP are now present in countries world-
wide [5] and pose a large threat to healthcare facilities both in the US and abroad due to
limited treatment options and mortality rates of up to 40% [8].
KPCs are encoded by the blaKPC gene and are harbored on the transposon Tn4401,
allowing it to associate with many different plasmids and spread across many species [9].
However, the vast majority of KPC positive clinical isolates come from a handful of K.
pneumoniae sequence types (STs), with the majority in the US being ST258 [9]. In addition
to carbapenems, KPC positive ST258 isolates are often resistant to the majority of antibiotics
on the market, leaving few treatment options available [4].
1.3 Methods to study CRKP regional transmission
Due to the limited treatment options for individuals with CRKP, infection prevention is a
particularly important component of reducing prevalence and mortality. To improve infection
prevention efforts, we must better understand where transmission is occurring. Most studies
and intervention measures to date have focused on investigating and reducing transmission
within a single healthcare facility, but increasing evidence suggests that regional transmission
among healthcare facilities is common [10]. Therefore, it is important not only to understand
transmission dynamics within a single facility, but also how and where transmission occurs
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between facilities.
Efforts to study regional MDRO transmission across healthcare facilities have primarily
used mathematical modeling to probe MDRO spread due to patient transfer between facili-
ties [11, 12]. One strength of these studies is that they are able to investigate the impact of
interventions on MDRO prevalence at different facilities. These studies have found that co-
ordinated regional control efforts lead to a much lower prevalence across regional healthcare
networks when compared to uncoordinated control efforts at individual facilities [13]. Sim-
ulations have also shown that targeted interventions at certain facilities, such as long-term
acute care hospitals (LTACHs), also decrease regional prevalence [14]. This is particularly
important as interventions to reduce transmission cannot practically be implemented at all
facilities in a regional network.
While modeling studies provide important insight into putative transmission dynamics
between regional healthcare facilities and allow us to probe the impact of various interven-
tions, models are by definition simplified versions of reality that make generalized assump-
tions and cannot capture all of the nuances that may influence true MDRO transmission
networks. As such, they do not allow us to investigate in detail actual networks of MDRO
transmission, nor specific transmission events. Epidemiological studies overcome some of
these limitations and are often used to investigate MDRO transmission within a given health-
care facility, and sometimes between healthcare facilities [15]. These studies usually perform
contact tracing to determine what patients and healthcare workers overlapped in the same
location, and thus may have transmitted the organism to one another. While these analy-
ses are very important and can be informative, they are extremely time intensive, and it is
often infeasible to determine the exact transmission pathway due to multiple overlap events
between different patients or healthcare workers, particularly in endemic settings [16].
One way to overcome the limitations of modeling and epidemiological studies is to use
whole-genome sequencing of isolates to gain a more nuanced understanding of the relatedness
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between different patient isolates [17]. This type of analysis is particularly informative
when combined with additional epidemiological information to investigate transmission. For
instance, a previous study performed a retrospective analysis combining patient transfer data
with whole-genome sequencing to gain a more detailed understanding of regional transmission
during a CRKP outbreak [18]. Integrating genomic and epidemiologic data allowed for a more
detailed understanding of directionality of transmission between facilities and identified an
intermediate facility that was important for regional spread.
While whole-genome sequencing has been effectively applied to studying regional trans-
mission in an outbreak setting, few studies have used this method to study endemic trans-
mission both within and between healthcare facilities. One study investigated methicillin re-
sistant Staphylococcus aureus transmission across the United Kingdom and found that, while
within facility transmission was common, spread between facilities also regularly occurred
[19]. However, non-comprehensive sampling limited their ability to compare prevalence at
different facilities and quantify the extent of transmission between facilities. Furthermore,
they did not incorporate patient clinical data into their transmission analysis, which could
provide additional insight into patient-level drivers of regional spread.
1.4 Methods to study CRKP evolution and adaptation
In addition to investigating transmission, it is also important to understand how nosocomial
pathogens adapt to the healthcare environment to better inform infection prevention and
control practices. ST258 contains two clades (clade I and clade II) with distinct genetic
backgrounds that have evolved independently of one another since around 2001 [20, 21, 22].
Clade I may have evolved from a clade II strain due to a recombination event in the K
antigen capsule polysaccharide biosynthesis gene region. Additionally, clade I ST258 strains
usually harbor a plasmid containing KPC-2, while clade II ST258 strains usually harbor a
4
plasmid carrying KPC-3. Furthermore, continued evolution of ST258 within the healthcare
setting leads to the persistence of some sublineages over time [23]. Adaptations that increase
virulence or cause antibiotic resistance are of particular clinical concern, as they may lead
to adverse patient outcomes [24].
Many studies investigating healthcare pathogen evolution have used experimental meth-
ods to study pathogen adaptation in a more controlled laboratory setting, either in vitro
or in model systems [25, 26, 27]. For instance, recent experimental results from studies in
mice indicate that different global CRKP strains are differentially virulent due to mutations
in, or disruption of, capsule biosynthesis genes [26]. Additionally, experimental evolution of
laboratory or clinical strains can shed light on trajectories of antibiotic resistance evolution
[28, 29]. These experiments provide valuable insights into a strain’s virulence and resistance
potential, and are critical for furthering our understanding of the molecular mechanisms
underlying these phenotypes. However, they do not capture the myriad of potential selective
pressures and interactions present in the healthcare setting that may influence evolutionary
trajectories and strain phenotypes in the natural environment, and do not provide insight
into the transmissibility of these strains among patients.
One way to overcome some of the limitations of laboratory studies is to investigate
pathogen evolution using comparative genomics of global clinical isolate collections. This
method identified genes associated with virulence and antibiotic resistance in global K. pneu-
moniae isolates [30]. Genome-wide association studies have also been extensively used to
identify the genotypic variation underlying resistance to specific antibiotics [31]. A strength
of these methods is that they derive inferences from evolutionary events that truly occurred
in the healthcare setting. However, the majority of these studies to date have used a global
sampling of isolates with little additional clinical metadata, limiting their ability to inves-
tigate the relationship between genomic variants, phenotypes, patient features, and strain
fitness. Furthermore, a global sample of isolates by and large only captures the successful
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end points of evolution. In contrast, capturing both successful and unsuccessful intermedi-
ates may yield information regarding various evolutionary trajectories, which could provide
insight into how to prevent the emergence of new epidemic strains.
1.5 Dataset used in this dissertation
To study the transmission and evolution of CRKP, we use a comprehensive set of clinical
isolates collected over the course of a year (August 2014 to July 2015) during a prospective
observational study in 21 LTACHs across the US. For each clinical isolate, we have Illumina
whole-genome sequencing data (BioProject accession no. PRJNA415194), antimicrobial sus-
ceptibility testing data for several antibiotics, and associated clinical metadata including pa-
tient comorbidities and previous antibiotic exposure. In addition, we have aggregate annual
patient transfer counts between facilities from Centers for Medicare and Medicaid claims
data for 2016. The vast majority (>90%) of isolates in this dataset are ST258; therefore, we
subset most of our analyses in all three chapters to ST258 to gain insight into the nuances of
this specific CRKP sequence type. The whole-genome sequencing data and clinical metadata
were used for all three chapters, the patient transfer data was used for chapter two, and the
antimicrobial susceptibility testing data was used for chapter four. More details about the
data can be found in the corresponding chapters.
1.6 Dissertation outline
This dissertation investigates transmission, infection, and antibiotic resistance evolution in
CRKP ST258. In chapter two I investigate how CRKP spreads within and between LTACHs.
In chapter three I uncover potential genomic drivers of colonization and infection. In chapter
four I identify distinct patterns of colistin resistance evolution and dissemination in different
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genetic backgrounds. For chapters two through four, I also developed a corresponding open
source R package to increase the ease with which other investigators can apply the methods
developed here to their own analyses. In chapter five I discuss bioinformatic, genomic, and
clinical implications of the findings from chapters two through four, and propose future
directions based on these implications.
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Chapter 2
Whole-Genome Sequencing to Identify Drivers of
Carbapenem-Resistant Klebsiella pneumoniae Transmission
Within and Between Regional Long-Term Acute-Care Hospitals
2.1 Preamble
This chapter uses whole-genome sequencing and aggregate patient transfer data to investigate
intra- and inter-facility transmission of CRKP in a regional network of LTACHs. We identify
several regional importation events, detect signatures of inter-facility transmission, and find
that facility prevalence is driven by intra-facility transmission. This transmission analysis
inspired us to create regentrans (https://github.com/Snitkin-Lab-Umich/regentrans), an
R package for studying regional pathogen transmission.
I performed all of the data analysis and generated all off the figures for this chapter. Other
co-authors performed isolate collection, detection of KPC-positive K. pneumoniae, antibiotic
susceptibility testing, whole-genome sequencing, and single nucleotide variant identification.
This work was published in Antimicrobial Agents and Chemotherapy in 2019:
Han JH, Lapp Z, Bushman F, Lautenbach E, Goldstein EJ, Mattei L, Hofstaedter CE,
Kim D, Nachamkin I, Garrigan C, Jain T. Whole-genome sequencing to identify drivers of
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carbapenem-resistant Klebsiella pneumoniae transmission within and between regional long-
term acute-care hospitals. Antimicrobial agents and chemotherapy. 2019 Nov 1;63(11).
I developed, or helped develop, most of the methods implemented in regentrans and wrote
draft functions for each method. regentrans has just been developed and does not yet have
use statics; however, several public health departments involved in the Centers for Disease
Control and Prevention Emerging Infections Program have expressed an interest in using the
package to perform their own analyses. The manuscript corresponding to the regentrans
package will be submitted for publication with the following co-authors:
Sophie Hoffman*, Zena Lapp*, Joyce Wang, and Evan Snitkin.
*Indicates co-first author
2.2 Introduction
Since first being reported in 2001 [6], epidemic lineages of carbapenem-resistant Klebsiella
pneumoniae (CRKP) have rapidly emerged and disseminated across global healthcare sys-
tems [32]. The limited treatment options for patients with CRKP infections has created
an urgent need for more effective strategies to prevent CRKP transmission [33, 34, 35, 36].
Historically, prevention of CRKP and other multi-drug resistant organisms (MDROs) has
been undertaken in a siloed manner, with interventions being applied at the level of individ-
ual healthcare facilities. However, it is increasingly appreciated that healthcare facilities are
highly connected to one another, with patients typically moving between different healthcare
facilities as part of their treatment and recovery [10].
Support for a regional approach to infection prevention comes from the success of coordi-
nated national interventions in controlling high-priority MDROs [37]. While a coordinated
national intervention is not currently logistically feasible in the United States, the infrastruc-
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ture for regional infection prevention is being advanced, particularly in collaboration with
regional and state public health departments [38, 39, 40]. What is now needed to facilitate
effective regional interventions are strategies to identify facilities with the highest transmis-
sion rates, methods to quantify how transmission at each facility influences colonization and
infection rates across the healthcare network and insights into the clinical and epidemiologic
drivers of both intra- and inter-facility transmission. With this level of understanding of
regional MDRO transmission, targeted interventions can be designed that leverage limited
resources to achieve the maximal possible decrease in regional MDRO prevalence [13]. In
a remarkably short time, whole-genome sequencing (WGS) has fundamentally changed the
resolution at which one can study the spread of bacterial pathogens [41]. Moreover, through
integration of genomic data with epidemiologic meta-data, the processes driving the spread of
these pathogens can be more clearly understood [42]. With respect to healthcare-associated
infections, recent work has shown that by integrating patient transfer data into genomic anal-
yses, the putative sites of transmission and the patient movements driving regional spread
can be identified [18, 43]. Here, we seek to take the next step in the application of genomic
epidemiology to regional infection prevention by integrating comprehensive genomic data,
statewide patient transfer networks and patient-level clinical meta-data to identify drivers
of the regional spread of CRKP.
2.3 Results
2.3.1 Overview of CRKP isolates from twenty long-term acute
care hospitals
Due to their chronically, critically ill patient population, long-term acute care hospitals
(LTACHs) are increasingly recognized as both major amplifiers and reservoirs of MDROs,
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including CRKP [44, 45]. To better understand the epidemiology of CRKP in LTACHs
across the United States we gathered clinical isolates and meta-data from LTACH patients
in four geographic regions, including a region with a high baseline prevalence of CRKP
[46]. A total of 451 unique CRKP culture episodes across the four geographic regions were
identified during the 12-month study period, with the majority (n=395; 87.6%) from eleven
Los Angeles area LTACHs (Table 2.S1). Demographic and clinical characteristics of patients
with CRKP clinical cultures are shown in Table 2.S2. Patients with CRKP had a high
rate of multiple comorbidities, and indwelling device and broad-spectrum antibiotic use
was common. Antibiotic susceptibility results for CRKP isolates are shown in Table 2.S3.
Nearly all of the isolates (>90%) demonstrated resistance to levofloxacin, ciprofloxacin, and
tobramycin. Resistance rates to colistin or polymyxin B were about 12%.
2.3.2 Phylogeographic analysis demonstrates that CRKP burden
in the Los Angeles area is largely due to endemic spread of
the ST258 epidemic lineage
Inference of CRKP sequence types from WGS data revealed that greater than 90% of LTACH
isolates belonged to the ST258 epidemic lineage (Table S4). To discern how circulating
LTACH strains relate to ST258 clones from other regions, a phylogeographic analysis was
performed using genome-wide variants identified in LTACH isolates as well as previously se-
quenced ST258 genomes with known geographic origins (Table 2.S5). The whole-genome
phylogenetic reconstruction in Figure 2.1 shows that the common ancestor of analyzed
genomes dates back to 2001, which is consistent with the timing of the first clinical ob-
servation of ST258 [47]. In addition, the phylogeny shows that cities in the Northeastern
United States played a prominent role in the early dissemination of this lineage to disparate
geographic areas. Focusing on the Los Angeles area LTACHs where we observe the high-
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est prevalence of CRKP, the reconstruction points to a small number of introductions into
the region as recently as 2012, with subsequent widespread dissemination across regional
healthcare networks.












Figure 2.1: Phylogeographic reconstruction of ST258 Klebsiella pneumoniae.
A phylogeographic analysis was performed on ST258 isolates from the current study, along
with previously sequenced ST258 genomes that had documented locations and dates of
isolation (See Table 2.S3). The x-axis corresponds to predicted dates of ancestral strains
and the colors of internal branches correspond to the predicted locations of ancestral strains.
Abbreviations: EUR: Europe; LA: Los Angeles; SA: South America; US-MA: Massachusetts;
US-MW: Midwest; US-NC: North Carolina; US-NE: North East; US-NY: New York; US-S:
South; US-W: West.
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2.3.3 Transmission rates between facilities are associated with pa-
tient transfer rates
To study regional transmission in more detail we next focused on Los Angeles LTACHs,
for which we had the largest number of isolates and a comprehensive sampling from eleven
different LTACHs. An LTACH-centric transmission map was constructed using 363 isolates
that represented independent ST258 acquisitions among 328 patients (Figure 2.2A) by first
performing ancestral reconstruction of LTACHs on the whole genome phylogeny. Intra- and
inter-facility transmission frequencies were then extracted from the ancestral reconstruction
as transitions between the same and different facilities, respectively (See Methods and Fig-
ures 2.S1 and 2.S2). Inspection of the map of inter-facility transmissions indicated higher
inter-facility transmission frequencies among geographically proximate facilities, which was
supported by a significant association between geographic proximity and transmission fre-
quency (Figure 2.S3, Mantel test p = 7 x 10-5). We hypothesized that the association
between transmission and geographic proximity was due to patient transfers preferentially
occurring between geographically proximate healthcare facilities [19]. To test this hypothe-
sis, we calculated the direct and indirect flow of patients between each pair of LTACHs using
a California statewide patient transfer network (See Methods). This patient transfer network
captures sequential utilization of different healthcare facilities based on Centers for Medicare
and Medicaid billing data and thereby provides quantitative information on how healthcare
facilities are connected to one another. As patients rarely transfer directly between LTACHs,
the connectivity between pairs of LTACHs was quantified using the maximal patient flow
path, regardless of the number of intervening facilities (See Methods). Comparison between
patient transfer and genomic networks confirmed that patient flow is strongly associated
with inter-facility transmission (Figure 2.S3). Of note, while the length and facility makeup
of the patient-transfer paths connecting LTACHs with and without transmission are similar
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(Figure 2.2B), the magnitude of patient flow is significantly higher for pairs of LTACHs with
predicted genomic transmission linkages (Figure 2.2C). Moreover, the association between ge-
nomically inferred inter-facility transmission and patient flow remains significant even when
there are multiple intermediate healthcare facilities connecting two LTACHs (Figure 2.2C),
indicating that indirect connections mediate regional spread over short time periods.
2.3.4 Facility-level CRKP prevalence is associated with intra-facility
transmission rates
With our genomic analysis revealing frequent transmission of CRKP between facilities, we
next evaluated whether facilities varied with regards to the magnitude of subsequent intra-
facility transmission associated with each importation event. Using the ancestrally recon-
structed whole genome phylogeny (Figure 2.S1), we quantified the fraction of patient isolates
attributed to intra-facility transmission versus importation (i.e., inter-facility transmission)
from another LTACH, revealing extensive variation in the ratio of intra-facility transmission
events per importation event (See Methods and Figure 2.S4). Moreover, those facilities with
the highest intra-facility transmission to importation ratio (”transmission ratio”) had the
highest CRKP prevalence (colonization or infection), suggesting that higher intra-facility
transmission rates drove facility-level variation in CRKP prevalence (Figure 2.3, Spearman
R = 0.75, p = 0.012).
2.3.5 Differences in intra-facility transmission ratios are associ-
ated with clinical characteristics of patients with CRKP
Notably, facility G had a markedly lower ratio of intra-facility transmission per importation
than all other facilities (Figure 2.3 and Figure 2.S5). While it was possible that the reduced




























































































































































































Figure 2.2: Regional transmission map for carbapenem-resistant K. pneumoniae (CRKP)
among eleven Los Angeles area LTACHs.
(A) Each gray circle represents a single LTACH, with the size of the circle corresponding to
the CRKP colonization/infection rate in that facility. The relative positions of the different
circles on the graph are based on their actual longitude and latitude. Arrows between
different LTACHs indicate that there was at least one predicted transmission between the pair
of facilities, with the thicker lines corresponding to larger numbers of predicted transmissions.
To highlight inter-facility transmissions between facilities with more linkages than expected
by chance, only links between facilities whose isolates cluster on the whole genome phylogeny
more than in randomly permuted phylogenies are shown (P < 0.1; See Methods). (B) Paths
of maximum patient flow between each pair of LTACHs were extracted from the statewide
patient transfer network and categorized into path motifs based on the types of facilities
on the paths (LT – long-term acute care hospital, ST – short-stay hospital, SNF –skilled
nursing facility). The fraction of LTACH pairs (y-axis) whose maximum flow paths were
assigned to each path motif (x-axis) was determined for LTACH pairs with and without
genomic transmission linkages. (C) Patient flow between LTACHs was compared for pairs
of LTACHs with and without genomic transmission linkages. Pairs of LTACHs were binned
into groups based upon the number of intervening facilities on the maximal patient flow
path between those LTACHs (e.g. 0 – direct transfer between LTACHs, 1 – one intervening
facility, etc.). Significance was assessed using a Wilcoxon rank-sum test.
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Figure 2.3: Facility colonization/infection rate associated with ratio of intra-facility trans-
missions per importation.
Each diamond represents one of the eleven Los Angeles area LTACHs, with the x-axis showing
the colonization/infection rate within the LTACH and the y-axis showing the number of intra-
facility transmissions per importation, as inferred from the genomic transmission network
(See Figure 2.S3). The CRKP colonization/infection rate for a facility was calculated as the
total number of colonization/infection episodes divided by the number of beds.
vention measures, we hypothesized that it may also be that the clinical characteristics of
facility G’s CRKP-positive patients make them less likely to transmit to other patients. To
test whether the decreased transmission ratio in facility G could be due to clinical char-
acteristics of CRKP-positive patients, we performed post hoc analyses comparing CRKP
population characteristics between patients from facility G and the three facilities with the
highest transmission ratios (facilities A, D, and F – Table 2.1). Patients with CRKP in the
facilities with high intra-facility transmission ratios compared to those in facility G were of
significantly older age (median 72 years versus 57 years, respectively; p = 0.008); had higher
rates of certain comorbidities including chronic kidney disease and/or requirement for dialy-
sis (43% versus 19%, respectively; p = 0.045), and a diagnosis of malnutrition and/or being
underweight (34% versus 0%, respectively; p = 0.003); and had higher rates of carbapenem
use in the 30 days prior to CRKP isolation (44% versus 13%, respectively; p = 0.02). To
assess whether these differences in patient characteristics applied to patients without CRKP,
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we conducted post hoc analyses of data collected from patients with carbapenem-susceptible
Klebsiella pneumoniae (CSKP) infection at the same four facilities. Comparison of clinical
characteristics of CSKP patients from low and high CRKP transmission facilities revealed
only a difference in their rate of chronic kidney disease, but in the opposite direction as with
CRKP patients (Table 2.S6). This result supported the lower transmission ratio at facility G
being driven in part by clinical characteristics of putative transmitters (e.g., CRKP-positive
patients), and not of the susceptible population (i.e., CSKP patients). Lastly, to determine
whether the association between clinical characteristics of CRKP patients and transmission-
ratio extended to all LTACHs, we compared the clinical characteristics of CRKP and CSKP
patients to the CRKP transmission-ratio using Spearman rank correlations (Figures 2.S6,
2.S7, 2.S8 and 2.S9) and found consistent, although not statistically significant, trends for
age (CRKP: R = 0.53, p = 0.1; CSKP R = 0.24, p = 0.49), chronic kidney disease (CRKP:
R = 0.6, p = 0.056; CSKP R = -0.29, p = 0.38), malnutrition (CRKP: R = 0.58, p = 0.066;
CSKP R = 0.36, p = 0.27) and carbapenem use (CRKP: R = 0.46, p = 0.15; CSKP R =
-0.17, p = 0.61).
2.4 Discussion
We performed WGS on 450 CRKP isolates from patients residing in four regional networks
of LTACHs. Placing these isolates in the context of previously sequenced clinical isolates
from around the world suggested a small number of importation events into each region,
followed by widespread dissemination across regional healthcare networks. Focusing on the
Los Angeles area LTACHs, where CRKP is highly prevalent, we observed that the density
of transmission between LTACHs was associated with the rates of patient flow between
those facilities. However, despite inter-LTACH transmission being common, our analysis
suggests that variation in CRKP prevalence across LTACHs was driven by differences in
17
Table 2.1: Clinical characteristics of patients with CRKP from facilities with high
(facilities A, D and F) versus low (facility G) ratios of intra-facility transmissions per
importation.
Variable, n (%)




A, D, F G
n = 163 n = 16
Age, median (IQR) 72 (65, 82) 57 (47, 76) 0.008 *
Male sex 93 (57) 5 (31) 0.07
LTACH LOS prior to culture, median (IQR) 26 (7, 53) 25 (10, 32)
0.58
Comorbidities
Congestive heart failure 32 (20) 1 (6) 0.31
Cirrhosis 12 (7) 0 (0) 0.61
Malignancy (solid or liquid) 19 (12) 1 (6) >0.99
Brain injury 36 (22) 2 (13) 0.53
Pulmonary disease 37 (23) 1 (6) 0.2
Acute or chronic respiratory failure 71 (44) 8 (50) 0.79
Severe chronic kidney disease (stage IV or ESRD on dialysis) 70 (43) 3 (19) 0.045*
Ventilator-dependent respiratory failure 54 (33) 2 (12) 0.16
Malnutrition/underweight 56 (34) 0 (0) 0.003*
Stage IV/V decubitus ulcer 40 (25) 2 (13) 0.37
Antibiotic use in prior 30 days, receipt of ≥ 48 hours
Carbapenem 72 (44) 2 (13) 0.02*
Fluoroquinolones 25 (15) 3 (19) 0.72
Aminoglycosides 42 (26) 1 (6) 0.12
Cefepime 33 (20) 3 (19) >0.99
Polymyxin/colistin 25 (15) 0 (0) 0.13
Anti-pseudomonal 104 (64) 8 (50) 0.29
Indwelling devices
Tracheostomy 126 (77) 9 (56) 0.06
Central venous catheter 101 (62) 9 (56) 0.78
Urinary catheter 96 (59) 8 (50) 0.6
Abbreviations: CRKP, carbapenem-resistant K. pneumoniae; IQR, interquartile range;
LTACH, long-term acute care hospital; LOS, length of stay; ESRD, end-stage renal dis-
ease.
18
intra-facility transmission rates. Lastly, we found that the facilities with the highest and
lowest predicted rates of intra-facility transmission differed in the clinical characteristics of
their CRKP patients, supporting the hypothesis that characteristics of CRKP patients may
contribute to risk of transmission. In total, these findings demonstrate the capacity for
WGS to reveal where regional transmission of endemic MDROs is occurring, and through
integration with clinical and epidemiologic meta-data to provide insight into the external and
internal forces driving MDRO colonization and infection rates within healthcare facilities.
Consistent with previous studies, we observed that patient transfer rates between health-
care facilities were associated with inter-facility transmission (i.e., importation) [19]. How-
ever, we noted that while the association between inter-facility transmission and patient flow
was robust, it was imperfect, with multiple instances of high transmission rates between fa-
cilities with low patient flow and low transmission rates between facilities with high patient
flow (Figure 2.S3). There are potential technical explanations for these deviations, includ-
ing patients with CRKP traversing healthcare networks differently than patients from the
utilized Centers for Medicare & Medicaid Services claims database as a whole, limitations
in the use of billing data to capture patient movement or unsampled CRKP cases leading
to missed inter-facility transmissions. Given the common practice of using patient transfer
data to model regional transmission of MDROs [11, 48], it will be important to understand
these discrepancies and determine whether patient transfer patterns alone can be used to
model endemic spread. A potential limitation in relying solely on patient transfer patterns
is a lack of consideration of uneven risk for transmission among different patient populations
and healthcare facilities, both of which are suggested by our data in the form of high-risk
patients and high-transmission facilities.
Previous studies have suggested that LTACHs play an important role in regional MDRO
proliferation, acting as sites for uncontrolled transmission and sources of MDRO-colonized
patients who move to other healthcare facilities [49, 50, 51]. Our data support these previ-
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ous observations, with strains from LTACHs spreading via the patient transfer network, and
CRKP transmission occurring within each LTACH. However, despite all LTACHs harboring
critically ill patient populations, we found extensive variation in the amount of intra-facility
transmission per importation across eleven Los Angeles area LTACHs. This result indi-
cates that LTACHs may not all be equivalent with respect to their overall contribution to
regional MDRO prevalence. An important consideration when interpreting these results is
the unmeasured contribution of asymptomatically colonized patients. Given reports that the
relative burden of asymptomatic carriage with CRE may be high [52], it will be important in
future studies to validate these results using combinations of clinical and active surveillance
cultures. However, we hypothesize that our study design and analysis strategy reduce the
impact of not capturing asymptomatic carriers. In particular, previous reports indicate that
frequency of asymptomatically colonized patients is markedly lower in high acuity patients
[53], and our use of aggregate estimates of intra- and inter-facility transmission increases
robustness to missing transmission intermediates, so long as they are not biased towards
particular facilities.
Most infection prevention strategies that target already infected patients (e.g. cohort-
ing of infected patients) assume that all carrier patients pose an equivalent risk of onward
transmission to other patients. The identification of factors associated with increased risk
of transmission may facilitate more targeted infection prevention strategies that allocate re-
sources to the management of high-risk patients. Here, we identify several clinical factors
that are preferentially associated with CRKP patients from high intra-facility transmission
facilities. Three of the clinical characteristics associated with CRKP patients from high
intra-facility transmission facilities - carbapenem use, malnutrition and older age, are associ-
ated with disruption of the gut microbiota [54, 55, 56], supporting overgrowth of colonizing
CRKP in the gut as driving CRKP transmission [57]. If this finding proves generalizable,
it would indicate that an effective anti-transmission therapeutic would only need to reduce
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colonization density in carrier patients, as opposed to completely decolonizing them. While
the relatively small number of patients in our study necessitates that future studies be un-
dertaken to validate these specific clinical findings, the clear clinical interpretation of these
patient factors provides support for the integration of genomic and clinical data as a strategy
to identify drivers of uneven MDRO transmission across regional healthcare facilities.
There are several potential limitations in this study. First, we did not have access to ad-
mission screening rectal cultures for CRKP and therefore were not able to evaluate the contri-
bution of asymptomatic gastrointestinal colonization to intra-facility transmission. While we
believe future analysis should focus on the additional potential contribution of asymptomat-
ically colonized patients to regional transmission in these LTACHs, our ability to reconstruct
inter-facility transmission networks that are consistent with healthcare utilization patterns,
using only clinical specimens, provides support for regional surveillance programs grounded
in comprehensive clinical collections [58]. Second, we did not have access to isolates from
other facilities in the region (e.g., acute care hospitals) that may play a significant role in
CRKP transmission. However, restricting our analysis to LTACHs still allowed us to dis-
cern regional transmission patterns that were consistent with patient flow between facilities,
and suggests that when combined with comprehensive patient transfer networks, WGS of
isolates from a targeted set of high-burden facilities can allow for monitoring the regional
dissemination of MDROs [59].
In conclusion, by integrating WGS with epidemiologic patient and facility data, we were
able to reveal pathways and drivers of CRKP spread within and between regional LTACHs.
The ability to tease apart the relative contributions of inter- and intra-facility transmission
across regional healthcare facilities, and to identify drivers of these processes, is a critical first
step in the development of effective regional interventions to control the spread of MDROs.
We believe that this work exemplifies that the tools and resources now exist to usher in an




A prospective, observational study was performed in LTACHs within the Kindred Healthcare
network from August 1, 2014 to July 25, 2015. A total of 20 LTACHs from four regional
networks were included: 11 LTACHs in the Los Angeles, CA area; 1 LTACH in San Diego,
CA; 6 LTACHs in the Houston, TX area; and 2 LTACHs in the Tampa, FL area. These
LTACHs were selected because all Kindred LTACHs in these regions are serviced by one
central microbiology laboratory (Rancho, CA; Houston, TX; and Tampa, FL), thereby en-
suring complete ascertainment of CRKP cultures. These regions were also selected based on
variation in CRKP prevalence (e.g., LTACHs in the Los Angeles area were specifically in-
cluded given their high prevalence of CRKP [59]. All study LTACHs routinely implemented
contact precautions for patients with CRKP.
The study was reviewed and approved by the Institutional Review Board of the University
of Pennsylvania with a waiver of informed consent.
Detection of KPC-positive K. pneumoniae and antibiotic susceptibility testing
All CRKP isolates during the study period were shipped to the core research laboratory
of the Clinical Microbiology Laboratory at the Hospital of the University of Pennsylvania
(HUP) for further testing. Confirmation that isolates were K. pneumoniae was performed
using PCR for detection of the mdh gene, and through standard biochemical testing [60].
Isolates were subsequently tested for the presence of the blaKPC-1 gene using primers as
previously described [6], and following the HUP Clinical Microbiology Laboratory protocol.
Confirmation of carbapenemase activity was performed using the Rosco Diagnostica Rapid
CARB kit (Rosco Diagnostica A/S, Tasstrup, Denmark).
Results of antibiotic susceptibility testing for all CRKP isolates were obtained from the
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participating regional laboratories, including for colistin/polymyxin B. Because susceptibil-
ity testing for tigecycline was not routinely performed, testing was done at the HUP Clinical
Microbiology Laboratory for all isolates using the Kirby-Bauer diffusion method and follow-
ing routine laboratory protocol. Susceptibility to colistin or polymyxin B and tigecycline was
defined as an MIC of ≤ 2 µg/mL, in accordance with European Committee on Antimicrobial
Susceptibility Testing criteria [61].
Whole-genome sequencing and single nucleotide variant identification
WGS was performed on all study isolates at the PennCHOP Microbiome Center at the
University of Pennsylvania. Genomic DNA was extracted from isolates using the DNeasy
Blood & Tissue kit (Qiagen, Venlo, the Netherlands). Libraries were prepared from 1 ng
extracted DNA using the NexteraXT DNA Sample Preparation Kit (Illumina, Inc., San
Diego, CA). Library concentration was assessed using the Quant-iT PicoGreen dsDNA Assay
Kit (Life Technologies, Waltham, MA) and fragment size was estimated using the Fragment
Analyzer (Advanced Analytical Technologies, Inc., Ankeny, IA). Libraries were pooled in
equal molar quantities and sequenced on the Illumina HiSeq 2500 in Rapid Run mode to
obtain 2x250 bp reads. Resulting fastq files were demultiplexed using DNAbc (https://
github.com/PennChopMicrobiomeProgram/dnabc) with two allowed barcode mismatches.
An average of 1.7 million read pairs were obtained per sample (Table 2.S4). Sequence data
is available under Bioproject #PRJNA415194.
2.5.2 Single nucleotide variant identification
Quality of raw reads was assessed with FastQC [62], and Trimmomatic [63] was used for
trimming adapter sequences and low quality bases. Variants were identified by: 1) mapping
filtered reads to the finished KPNIH1 reference genome (Genbank accession no. CP008827)
using the Burrows–Wheeler short-read aligner (BWA) [64], 2) discarding PCR duplicates
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with Picard [65], and 3) calling variants with SAMtools and bcftools [66]. Variants were
filtered from raw results using GATK’s VariantFiltration (QUAL > 100, MQ > 50, > 10
reads supporting variant, FQ < 0.025) [67]. In addition, a custom Python script was used
to filter out single nucleotide variants that were <5bp in proximity to indels. Lastly, for
phylogenetic analyses, Gubbins was applied to filter out recombinant variants [68].
Phylogeographic analysis of CRKP spread across the United States
Study isolates were compared to publicly available previously sequenced CRKP isolates from
various geographic locations to place regional CRKP populations in a broader context (Table
2.S3). The majority of analyzed CRKP isolates were from acute care hospitals in the United
States (in outbreak and non-outbreak settings) and included only clinical cultures (e.g. no
active surveillance cultures). Phylogeographic analyses were performed in BEASTv2.4.7 [69]
using a GTR DNA substitution model, an uncorrelated lognormal (UCLN) relaxed molecular
clock with a Gamma(0.001,1000) prior on the mean, and a Bayesian skyline population
growth model with five groups. A strict molecular clock was rejected because zero is not
in the 95% HPD of the coefficient of variation when using a UCLN clock model, and a
constant population size was rejected because zero is not in the 95% HPD of the growth
rate when using an exponential population model. Bayesian skyline was selected over the
exponential population model using path sampling with 100 steps of 1 million iterations
each. A Beta(alpha=0.3,1) distribution was used to determine the power posteriors of the
steps. For each phylogeographic analysis, four independent Markov chains were run with
100 million iterations and a burn-in of 10 million. A maximum likelihood (ML) starting tree
generated in RAxML [70] was used to accelerate MCMC chain convergence. Individual and
combined chains were analyzed in Tracer v1.6.0 [71] to confirm convergence and adequate
mixing. Maximum clade credibility (MCC) trees of the combined chains were generated
using TreeAnnotator v2.4.7. These summary trees were used for all subsequent analyses.
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2.5.3 Construction of regional transmission networks using max-
imum likelihood methods
A genomic transmission map was created among the eleven Los Angeles area LTACHs with
the aim of evaluating inter- and intra-facility transmission links. First, a ML tree recon-
struction was performed with IQTREE v1.5.5 [72] on variants identified by alignment to the
KPNIH1 reference genome using ultrafast bootstrap with 1000 replicates (-bb 1000) [73].
ModelFinder [74] limited to ascertainment bias-corrected models (-m MFP-ASC) was used
to identify the best model (TVM+ASC+R4) based on Bayesian Inference Criterion (BIC)
across 10 replicates. Of the trees produced from the best-fitting model (n=2), the tree with
the highest likelihood was used for all subsequent analyses. For subsequent regional trans-
mission analyses, multiple isolates from the same patient while at the same facility were
collapsed if they formed homogeneous phylogenetic sub-clades, and were retained otherwise
as representing independent acquisition events.
Regional transmission networks were constructed by first calculating the relative likeli-
hoods of unobserved ancestral outbreak strains being associated with each facility. Ancestral
reconstruction was performed using the rerooting method for maximum likelihood ancestral
reconstruction, as implemented in phytools [75]. Inter-facility transmissions were extracted
from the ancestrally reconstructed phylogeny if a branch connected two nodes with different
ancestral state assignments. Intra-facility transmissions were tabulated as branches connect-
ing tips to an internal node with the same ancestral state. To account for importation into
facilities, the number of transmissions into a given facility was subtracted from the total
intra-facility transmission count.
Lastly, to quantify the strength of transmission linkages between facilities, while con-
trolling for the total number of isolates associated with the pair of facilities, we devised
a permutation test. In particular, the number of subtrees containing only isolates from a
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given pair of facilities was calculated for the original phylogeny, and then compared to 1000
permuted phylogenies in order to compute an empiric p-value. To maintain the high level
of intra-facility transmission in the actual data, permutation was done at the level of sub-
trees instead of isolates, wherein subtrees containing only isolates from a single facility were
randomly swapped for one another.
2.5.4 Construction of regional transmission networks using BEAST
To validate the results from our maximum likelihood regional transmission network (Figure
2.S1), we performed a parallel analysis in BEAST (Figure 2.S2). The existence of temporal
signal in the data was confirmed by using the ML tree to compare the root-to-tip regression
estimate of the time to the most recent common ancestor (TMRCA) of the isolates using
the true sequence isolation dates to that of randomly permuted isolation dates. A dated
phylogeny of the Los Angeles area LTACH isolates was reconstructed in BEAST2 [69], with
the same variants used in ML tree reconstruction, under a model averaging nucleotide substi-
tution model (bModelTest [76]), an uncorrelated lognormal (UCLN) relaxed molecular clock
[77] with a Gamma distribution prior (shape=0.1, scale=0.01) on the mean, a Bayesian
skyline population model with five groups, and a discrete trait (facility). The number of
invariant As, Cs, Gs, and Ts was included in the XML, and the ML tree was used as the
starting tree to speed up convergence. Six 100,000,000 chain-length runs, confirmed to have
reached convergence using Tracer v1.7.1 [71], were combined after removing 20% burn-in.
A maximum clade credibility (MCC) tree was constructed using TreeAnnotator v2.4.7 and
used for all subsequent analyses. The inter-LTACH transmission network was then extracted
from the ancestrally reconstructed tree as described in the main Methods for the maximum
likelihood reconstruction.
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2.5.5 Analysis of LTACH CRKP rates
Evaluation of CRKP rates for the study LTACHs was performed using the following defini-
tions:
1. Standardized CRKP rate for a specific facility was calculated as the total number
of unique colonization and infection episodes in that facility divided by the number
of facility beds (Table 2.S6). For this calculation, unique colonization and infection
episodes were determined by collapsing multiple isolates from the same patient if they
clustered on the phylogeny. Standardized CRKP rate for a specific facility includes
both intra-facility and inter-facility transmission (defined below).
2. Intra-facility transmission per importation ratio for a specific facility was quantified as
the number of isolates attributed to intra-facility transmission divided by the number
of isolates attributed to importation (i.e., inter-facility transmission), as determined
from post-hoc analysis of the ancestrally reconstructed phylogeny (See Methods above).
Of note, because we only sequenced isolates from LTACHs, intra-facility transmissions
could include transmissions that occurred at surrounding non-LTACH facilities, if mem-
bers of transmission chains from surrounding facilities independently transferred to the
LTACH.
Geographic maps including LTACH locations were created using LTACH addresses and
latitude/longitude using R’s network package, v.1.13.0 [78].
2.5.6 Construction and analysis of California statewide patient
transfer networks
Claims data from the Centers for Medicare & Medicaid Services (CMS) were used to extract
patient transfer networks connecting healthcare facilities in California from January 1, 2016
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to December 31, 2016. CMS claims data captures admissions and discharges from health-
care facilities for all fee-for-service beneficiaries nationally. However, Medicare requires a
qualifying stay in a hospital prior to admission to a skilled nursing facility (SNF) and will
only cover the first 100 days of your SNF visit, thus not all SNF stays are included in the
claims and some SNF discharges will not represent true discharges but a switch to private
coverage. Claims data were used to capture direct (i.e., transfers with no more than one
day between the discharge at facility 1 and admission at facility 2) and indirect transfers
(i.e., readmissions with an intervening stay in the community less than a pre-specified time).
Healthcare facilities included acute care hospitals, SNFs, and LTACHs, including the eleven
Kindred Los Angeles area LTACHs evaluated in the present study.
This patient transfer network was considered a directed weighted graph such that nodes
in the patient transfer network corresponded to healthcare facilities and edges corresponded
to patient transfers from source to destination facility. Raw edge weights across the network
(count of transfers from facility X to facility Y within 365 days) were normalized by dividing
by the total number of outgoing patient transfers at the source facility (i.e., out strength).
This normalization resulted in edge weights that represented the probability of a patient
going to facility Y if he/she was discharged from facility X. The length of the directed
edge from X to Y was defined as the logarithm of the inverse probability. The shortest
path between each pair of LTACHs was determined using these edge lengths and Dijkstra’s
algorithm [79]. All network analyses and visualization were performed in R igraph v1.2.0
[80].
The maximum patient flow between each pair of LTACHs was compared to the inferred
genomic transmission network and the driving distance between facilities using the Mantel
test [81] in the R package vegan v2.5-2 [82]. The number of importations from source to
destination facility was normalized by the total number of importations to the destination
facility. For Figure 2.S3, patient transfer and genomic transmission matrices were made
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undirected by adding the matrix to its transpose and dividing by two. Driving distance
between facilities was determined using the gmapsdistance R package [83].
2.5.7 Analyses of patient characteristics
Comorbididty and medication data were acquired via automated queries from Kindred’s
electronic medical record system, ProTouch. Comorbidities were ascertained using diagnosis
codes, and medications were ascertained using pharmacy administration data. Descriptive
analyses were performed to summarize information of patients with CRKP, including demo-
graphics, comorbidities, and presence of indwelling devices. Bivariable analyses of CRKP and
CSKP population characteristics between select facilities were performed using the Fisher’s
exact test for categorical variables and the Wilcoxon rank-sum test for continuous variables.
For all calculations, a two-tailed P-value of ¡0.05 was considered significant. All analyses
were performed using STATA v.14.0 (StataCorp, College Station, Texas).
2.6 Supplement
2.6.1 Supplementary tables and figures
For supplementary material visit https://aac.asm.org/content/63/11/e01622-19/figures-only.
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Chapter 3
Patient and Microbial Genomic Factors Associated With
Carbapenem-Resistant Klebsiella pneumoniae Extraintestinal
Colonization and Infection
3.1 Preamble
This chapter explores the relationship between extraintestinal colonization and infection in
clinical CRKP isolates using machine learning. We investigate the predictive power of clini-
cal and genomic features in distinguishing between colonization and infection, and identify a
sublineage of CRKP that appears to have evolved an increased affinity for colonization of the
respiratory tract, followed by increased infectivity due to acquisition of a virulence factor.
This analysis inspired us to create mikropml (https://github.com/SchlossLab/mikropml),
an R package for performing machine learning analyses.
I performed all of the data analysis and generated all off the figures for this chapter. Other
co-authors gathered the clinical data and defined isolates as colonization vs. infection. This
work was published in mSystems in 2021:
Lapp Z, Han JH, Wiens J, Goldstein EJ, Lautenbach E, Snitkin ES. Patient and Microbial
Genomic Factors Associated with Carbapenem-Resistant Klebsiella pneumoniae Extrain-
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testinal Colonization and Infection. Msystems. 2021 Apr 27;6(2).
I developed the grouping aspect of mikropml used in this chapter, wrote the function to
preprocess the data for machine learning, debugged several functions, and wrote checks and
unit tests. As of April 28, 2021 mikropml has 2,044 downloads. The manuscript correspond-
ing to mikropml was submitted for publication with the following co-authors:




Infections due to multidrug resistant organisms lead to hundreds of thousands of deaths
worldwide each year [84]. Carbapenem-resistant Enterobacterales (CRE) are a critical-
priority antibiotic resistance threat that has emerged over the past several decades, spread
across the globe, and accumulated resistance to last-line antibiotic agents [5, 85]. In the
United States (U.S.), CRE infections are primarily caused by the sequence type (ST) 258
strain of carbapenem resistant Klebsiella pneumoniae (CRKP), which has become endemic
in regional healthcare networks [85, 32, 36, 86, 46]. In this background of regional endemic-
ity the risk of patient exposure to CRKP is high, as evidenced by alarmingly high rates of
colonization, especially in long-term care settings [46, 45]. However, even among critically
ill patients residing in long-term care facilities, not all colonized patients develop clinical
infections that require antibiotic treatment [46, 52]. Currently, our understanding of the
factors that influence whether a colonized patient develops an infection is incomplete.
In addition to clinical characteristics of patients [87], the genetic background of the
colonizing strain may also influence the risk of infection, as there is extensive intra-species
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variation in antibiotic resistance and virulence determinants harbored by K. pneumoniae
[85]. To date, most studies of virulence determinants have been carried out in model systems
[25] or examined in human populations without considering patient characteristics or clinical
context [26, 30]. One recent study investigated virulence determinants in K. pneumoniae
clinical isolates while controlling for patient characteristics [88]. However, this was a single-
site study with a focus on carbapenem-susceptible K. pneumoniae, thereby not addressing the
impact of genomic variation in antibiotic-resistant lineages that circulate in global healthcare
systems.
Here, we sought to understand the importance of both patient factors and genomic fea-
tures in determining whether a patient is colonized or infected with CRKP ST258. Im-
portantly, we restricted our comparison to patients with extraintestinal CRKP colonization
versus infection. We reasoned that this comparison would reveal the patient and microbial
factors that influence risk for infection when CRKP is present in an extraintestinal site;
eliminating confounding by factors associated with translocation from the gastrointestinal
tract. To gain an unbiased assessment of influential patient an microbial factors in a high-
risk population we leveraged a comprehensive set of all clinical isolates and patient metadata
collected from 21 long-term acute care hospitals (LTACHs) across the U.S. over the course
of a year. Machine learning models rigorously trained and tested on these data revealed
that patient and microbial factors were similarly predictive of CRKP ST258 colonization
versus in infection, indicating that both contribute to infection risk. Moreover, examination
of predictive genomic features revealed genetic variation within the epidemic ST258 lineage




Of 355 clinical CRKP isolates from 21 LTACHs across the U.S. (15), we classified 149 (42%)
of the isolates as representing extraintestinal infection based on modified National Healthcare
Safety Network (NHSN) criteria [89] (Figure 3.S2, Tables 3.S1-3). The rest of the isolates
were classified as representing extraintestinal colonization. Stratified by anatomic site, we
classified 29/29 (100%) blood isolates as infection, 69/196 (35%) respiratory isolates as infec-
tion, and 51/130 (39%) urinary isolates as infection (Table 3.S3). More than 90% of patient
isolates were from the epidemic CRKP lineage ST258 (Table 3.S1). Patients harboring dif-
ferent sequence types of CRKP showed no significant differences in infection/colonization
status or anatomic site of isolation, and no substantive differences in clinical characteristics
(see supplementary material). Thus, we decided to limit our analysis to ST258 to improve
our ability to discern whether genetic variation within this dominant strain is associated
with infection.
3.3.1 The CRKP epidemic lineage ST258 shows evidence of sub-
lineage variation in virulence and anatomic site of isolation
We next evaluated if there exist sub-lineages of ST258 with altered virulence properties
by looking for clustering of isolates by infection on the whole-genome phylogeny (Figure
1; see supplementary methods) [90]. Infection status was non-randomly distributed on the
phylogeny (p=0.002), supporting our hypothesis that the genetic background of CRKP influ-
ences infection. We performed a similar clustering analysis to look at potential niche-specific
adaptation to certain anatomic sites (Figure 3.1), and found that respiratory (p=0.001) and
urinary (p=0.013) isolates cluster on the phylogeny, but blood isolates do not (p=0.21). This
analysis indicates that, in addition to patient features, intra-strain variation in virulence and
adaptation to the urinary and respiratory tract might influence whether patients develop an
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infection.
Figure 3.1: Infection and anatomic site cluster on the phylogeny.
Maximum likelihood phylogenetic tree of all isolates including infection or colonization clas-
sification for each isolate and anatomic site of isolation. The scale bar to the right of the
phylogeny shows the branch length in substitutions per site. Testing for non-random dis-
tribution of isolates on the phylogeny (see supplementary methods) revealed clustering of
infection, respiratory, and urinary isolates on the phylogeny, respectively.
3.3.2 Both patient and CRKP ST258 genetic characteristics are
weakly predictive of infection, with relative performance be-
ing highly facility-dependent
We next performed machine learning using L2 regularized logistic regression to quantify the
ability of patient and microbial genetic characteristics to predict CRKP ST258 infection
(Figure 3.S1). To prevent over- or under-fitting and control for facility-level biases, we
generated 100 train/test data splits, wherein a given LTACH was only included either in the
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train or test set. Each LTACH occurred a median of 24 times (range 13-32) in the test data
split. In this way, we were able to identify patient and CRKP ST258 strain characteristics
consistently associated with infection or colonization across data splits, and thus across
patient populations in different healthcare facilities.
First, we sought to understand if patient and genomic features were individually predic-
tive of CRKP ST258 infection. To this end, we independently evaluated patient character-
istics as well as three different genomic feature sets for their ability to classify colonization
and infection. The three genomic feature sets were uncurated genomic (including single
nucleotide variants, indels, insertion elements, and accessory genes), uncurated grouped ge-
nomic (variants grouped into genes, akin to a burden test, e.g [91]), and curated genomic
(features identified using Kleborate [92]). Across the 100 different train/test splits, we ob-
served that the average predictive performance was weak, with each of the genomic and
patient feature sets predictive of infection to a similar degree (all 1st quartile area under the
receiver operating characteristic curves [AUROCs] > 0.5; median range=0.55-0.68; Figure
3.2A; AUPRC: Figure 3.S3A). Additionally, no one feature set was consistently the most
predictive (e.g. Figures 3.2B, 3.2C; all comparisons p > 0.30, see supplementary methods
for p-value calculation). Furthermore, for each feature set the AUROCs were distributed
such that the test AUROC ranged from below 0.5 to over 0.7, depending on how the data
were split (i.e., which facilities appear in the train/test sets). This variation in model perfor-
mance across different train/test sets suggests that the association of CRKP ST258 strain
and patient characteristics with infection or colonization varies across facilities.
Integration of patient and CRKP strain features does not improve discriminative
performance of overall or anatomic site-specific models
To determine if the predictive power of patient and genomic features is additive, and if
combining these disparate feature sets improved validation on held-out facilities, we built
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Figure 3.2: Test AUROCs for various classifiers identifying CRKP colonization vs. infection
vary substantially across data splits.
(A) Test AUROCs for 100 L2 regularized logistic regression models different using train/test
splits. All isolates from a given LTACH were included in either the training split or the
testing split for each data split. We built models using five different feature sets, keeping
the same 100 data splits. AUROCs of different feature sets were not significantly different.
In the right two panels, the curated genomic feature set AUROCs are compared to: (B) the
uncurated genomic feature set AUROCs, and (C) the patient feature set AUROCs. Each
point is the resulting pair of AUROCs for models built with the same data split, but the two
respective feature sets. The dotted lines in all 3 panels indicate the AUROC for choosing an
outcome randomly (0.5); anything below the line is worse than random, and anything above
the line is better than random. The solid diagonal line in the right two panels is the line
y=x; points below the line correspond to a higher curated genomic AUROC for that data
split, and points above the line correspond to a higher uncurated genomic AUROC (B), or
patient AUROC (C), respectively. The colors in panels (B) and (C) correspond to the colors
in panel (A); the points in a given colored area indicate that that feature set had the higher
AUROC for that data split. In both cases, one feature set does not consistently outperform
the other (p=0.4; see supplementary methods for p-value calculation). AUROC=area under
the receiver operating characteristic curve.
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models including both patient and curated genomic features. The discriminative performance
of the models based on the combined feature set was not significantly greater than that
of the individual feature sets (Figure 3.2A, all p ≥ 0.20). Thus, despite variation in the
predictive capacity of genomic and patient features across facilities (Figure 3.2C), combining
the two sets did not improve overall performance. Furthermore, we found that there was no
significant difference in model performance between L2 regularized logistic regression, elastic
net, random forest, and support vector machines with a radial basis kernel (Figure 3.S3B,
all p > 0.1). Focusing on anatomic site-specific L2 regularized logistic regression models
revealed similar trends, where classification performances were similar for respiratory and
urinary specific models, and the relative predictive capacity of patient and CRKP ST258
strain features varied across facility subsets (Figure 3.S3C, S3D).
3.3.3 Some patient and genomic features consistently discriminate
colonization and infection
After evaluating the predictive capacity of models, we next sought to identify patient and
CRKP ST258 strain characteristics that are most associated with infection or colonization.
To this end, we identified those patient and genomic features that consistently improved
model performance across the 100 different data splits (see methods). Evaluating the im-
portance of features in this way provides insight into those characteristics that generalize
across different facility subsets. This approach was taken for both overall and anatomic site-
specific models to identify features predictive of different anatomic sites of infection (Figure
3.3, 3.S4).
Several patient features were consistently associated with infection in the overall analysis,
including presence of a gastrostomy tube, presence of a central venous catheter, acute kidney
injury, and severe chronic kidney disease (Figure 3.3), all markers of critically ill patients.
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Figure 3.3: Features consistently associated with colonization or infection sometimes differ
between the overall, respiratory, and urinary models.
Feature-specific improvement in model performance, measured as the mean difference be-
tween test and permuted AUROC (see methods), of features found to be consistently as-
sociated with colonization or infection in at least one of the following analyses: overall,
respiratory-specific, urinary-specific. We consider features to be associated with infec-
tion/colonization if the AUROC difference was greater than zero in over 75% of the 100
data splits. Each point is surrounded by two quantiles - a solid line for 25% to 75% (the
threshold used to select features) and a dotted line for 5% to 95%. The vertical solid black
line indicates a difference of zero (i.e. the feature provides no improvement to model perfor-
mance). Horizontal dotted lines separate features associated with urinary but not respiratory
isolates (top), both urinary and respiratory (or all) isolates (middle), or respiratory but not
urinary isolates (bottom). Bla=Beta lactamase, res=confers resistance to that antibiotic
class. AUROC=area under the receiver operating characteristic curve.
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Only a small number of genomic features were consistently associated with infection or colo-
nization (Figure 3.3). The genomic features associated with colonization were all antibiotic
resistance determinants. Conversely, all but one of the genomic features positively associated
with infection (3/4) are related to virulence. The ICEKp10 element is positively associated
with infection and carries colibactin and two different types of yersiniabactin, a previously
identified K. pneumoniae virulence determinant [26]. Colibactin is a toxin [85], and yersini-
abactin is an iron scavenging system that has been identified in previous animal and human
studies as being associated with virulence [85, 25]. Additionally, insertion sequence-mediated
disruption of the O-antigen biosynthetic gene kfoC was associated with respiratory infec-
tion (see methods and Figure 3.S5A for insertion sequence identification). The O-antigen of
lipopolysaccharide (LPS) is a known antigenic marker, although association with a specific
anatomic site has not been noted [93].
3.3.4 A sub-lineage of ST258 clade II appears to have sequentially
evolved enhanced adaptation for the respiratory tract and
increased virulence
We noted that kfoC disruption is largely confined to a sub-lineage of ST258 present across
12 LTACHs in California (Figures 3.4, 3.S5). Consistent with this feature being associ-
ated with respiratory infection, the disrupted kfoC lineage is enriched in respiratory isolates
(82/118, 69% of isolates in the disrupted kfoC lineage are respiratory isolates vs. 101/213,
47% in all other isolates; Fisher’s exact p=0.0001), suggesting that this lineage is associated
with increased capacity for respiratory colonization. Furthermore, a subset of isolates in the
disrupted kfoC sub-lineage harbor the ICEKp10 element containing yersiniabactin. Exam-
ination of these genetic events in the context of the whole-genome phylogeny revealed that
disruption of kfoC occurred first, followed by at least two different acquisitions of ICEKp10
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(Figure 3.4). Within the disrupted kfoC lineage, isolates with ICEKp10 are enriched in
infection (31/55, 56% of isolates with ICEKp10 are infection isolates vs. 16/63, 25% of
isolates without ICEKp10, Fisher’s exact p = 0.00065), supporting an increase in virulence
after acquisition of ICEKp10. It is important to note that the observed clinical associations
with ICEKp10 and kfoC disruption do not demonstrate causality, as we cannot rule out the
role of correlated genetic variation.
3.4 Discussion
There have been numerous studies aimed at identifying risk factors for healthcare-associated
infections caused by prominent antibiotic-resistance threats. For the most part, these studies
have found the dominant risk factors to be linked to the magnitude of exposure (e.g. length of
stay or colonization pressure), use of antibiotics, and overall comorbidity [94]. What remains
unclear is if in addition to these clinical features, the genetic variation in circulating resistant
lineages also contributes to patient risk of infection. Here, we addressed this question for
CRKP ST258 in a comprehensively sampled cohort of patients from 21 LTACHs across
the U.S. Overall, we found that, while neither patient nor CRKP ST258 genetic features
have high predictive accuracy on held-out test data, both feature sets were independently
associated with infection, with one or the other being more predictive on different facility
subsets. Moreover, the integration of clinical and genomic data led to the discovery of an
emergent sub-lineage of the epidemic ST258 clone that may have increased adaptation for
the respiratory tract, and is more strongly associated with infection.
One strength of our machine learning approach is that we were able to measure the
variation in discriminative performance across 100 train/test iterations that differed in which
facilities were included in train and test sets. We found that performance varied greatly
depending on how facilities were allocated to train and test sets, highlighting how smaller
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Figure 3.4: Select epidemiologic and genomic features visualized on the phylogeny indicate
that a sub-clade of ST258 clade II may exhibit enhanced niche-specific adaptation and vir-
ulence.
ST258 maximum likelihood phylogeny with the tip labels colored by KPC gene. The blue
box indicates the sub-lineage with apparent altered niche-specific adaptation that acquires
an additional virulence locus. The heatmap beside the tree indicates information about the
isolate. From left to right: if it is a respiratory isolate, if it is an infection isolate, if kfoC
is disrupted, and if it contains ICEKp10. Disrupted kfoC was associated with infection in
the overall and respiratory machine learning analyses and ICEKp10 presence was associated
with infection in the overall analysis. Note that the majority of isolates without disrupted
kfoC in that lineage contain a different O locus type (Figure S5A). The scale bar to the top
left of the phylogeny shows the branch length in substitutions per site. ybt=Yersiniabactin;
ybt0 and ybt17 are two ybtSTs defined by Kleborate.
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studies could overestimate or underestimate the discriminative ability of both their model and
individual features. Variation in model performance across facilities could be due to facility-
level heterogeneity leading to differences in the prevalence of predictive patient or genomic
features in the different test sets. For instance, certain facilities may have patient populations
skewed towards individuals with characteristics that are predictive of infection. Alternatively,
certain geographic regions may have CRKP ST258 strains that are more virulent than in
other regions. These differences could lead to a higher predictive power for certain facilities
compared to others. Another possible explanation for variation in model performance is
that the critically-ill nature of LTACH patients may be such that most patients are actually
highly susceptible to infection (i.e. many patients colonized with CRKP may ultimately
develop an infection). However, it is noteworthy that despite these potential challenges in
creating generalizable models, our analysis did yield predictors of infection and colonization
consistent across test sets, and thus across LTACHs.
We built classifiers including all genomic features as well as a curated subset of features
from Kleborate [92], and found that both are similarly predictive of infection. However,
while the uncurated feature set presented challenges with downstream interpretation, our
analyses on the curated genomic features [92] facilitated novel insights into potential evo-
lutionary trajectories of anatomic site-specific adaptation and virulence. For example, we
observed that disruption of the O-antigen biosynthetic gene, kfoC, is associated with isolation
from the respiratory tract. While we cannot determine from our machine learning analy-
sis if disruption of kfoC is directly causal, the biological plausibility of an altered O-antigen
structure mediating evasion of innate immunity and/or other beneficial interactions with the
host makes this a strong candidate for follow-up experiments. Supporting this hypothesis,
a previous study found that absence of O-antigen is associated with decreased virulence,
but not decreased intrapulmonary proliferation, in a murine model [95]. In addition, we
noted that a number of antibiotic resistance determinants were associated with coloniza-
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tion. We hypothesize that this observation could be a consequence of longer duration of
residence being associated with increased exposure to off-target antibiotics [96]. Finally, we
also saw evidence that, after acquiring the virulence factors yersiniabactin and colibactin on
the ICEKp10 element, the disrupted kfoC subclade became more strongly associated with
infection, supporting the idea that circulating ST258 sub-lineages can evolve to become both
hypervirulent and multi-drug resistant [97, 23, 98, 99].
It is important to note that the machine learning method we employed does not correct
for microbial population structure. We chose this method instead of alternative bacterial
genome-wide association methods because our primary interest was in quantifying the over-
all predictive capacity of bacterial genotype in a patient population that was collected in
a comprehensive and unbiased manner (i.e. all clinical isolates from 21 facilities over one
year). While alternative methods controlling for population structure may yield more precise
estimates of the contribution of individual variants, this would obfuscate the realized con-
tribution in our patient population and hinder direct comparison to the predictive capacity
of patient features. However, this then presented the challenge of interpreting our finding
that certain sub-populations of CRKP ST258 may differ in their predilection for causing
infections at different sites. For instance, the kfoC disruption is a lineage defining variant,
and in principle other variants that define this lineage could also be causal. Here, we limited
our analysis to a curated set of variants belonging to pathways known to be associated with
antibiotic resistance and virulence, and found that only kfoC disruption was associated with
increased respiratory infection, thus making it a strong candidate for follow-up in in vitro or
in vivo models [25]. To identify novel loci whose role in human infection may not be appre-
ciated both computational and experimental strategies may be employed to help prioritize
putative causal versus passenger variants. Computationally, investigators may search for ev-
idence of parallelism in genotype/phenotype associations, which would bolster confidence in
causality [100]. Alternatively, high-throughput screens of genetic mutants in relevant model
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systems can help prioritize candidates. Garnering further genomic or experimental support
for the direct role of a specific genetic variant would in turn increase the likelihood that those
genetic markers would be predictive in new strains and patient populations.
Our study also has several important limitations related to the data available. Specifi-
cally, extraintestinal CRKP colonization vs. infection for non-bloodstream isolates may be
difficult to discriminate using surveillance criteria and the clinical data that were available.
However, we based our definitions on established Centers for Disease Control and Preven-
tion criteria with modifications used previously [46]. Encouragingly, we were still able to
identify consistent predictors of infection, even with potential misclassifications. A second
limitation is that our dataset only included one clinical culture for the majority of patients,
meaning that we were unable to investigate clinical or genomic features that may be asso-
ciated with progression from colonization to infection. Furthermore, we do not have CRKP
rectal colonization isolates, and therefore cannot evaluate transition from rectal coloniza-
tion to other body sites. However, we hypothesize that comparing rectal colonization to
infection may be asking a subtly distinct question - namely bacterial genetic factors that
enable translocation from the gut to other body sites. In contrast, we hypothesize that our
study design is ideal to identify bacterial genetic factors associated with infection once at
a given body site. Additionally, we chose to focus our analysis on ST258 due to its dis-
proportionate presence in our dataset, but this makes it possible that our findings may not
generalize to other sequence types. Nevertheless, ST258 is the dominant clone in the U.S.,
and the methods we employed here can be used to study other sequence types and other
pathogens. Furthermore, our focus on the ST258 lineage led to the particularly notable
finding that even within an established endemic multidrug resistant lineage (that emerged
circa 2000 [22]), there is continued evolution that influences the manifestation and outcome
of infection. This highlights the importance of performing strain-specific analyses to identify
continued evolution and adaptation of hospital-associated lineages. We were also limited in
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the patient data included in our model. It is likely that important differences in underlying
patient conditions were not captured by the coarse clinical variables we included, and we
also did not account for differences in genetic variation in the host [101]. Other limitations
include that our study was restricted to LTACH patients and had non-random geographic
sampling. However, our restriction to LTACHs in endemic geographic regions has the benefit
of focusing on populations at disproportionate risk for CRKP infection [45].
In conclusion, we employed a machine learning approach to quantify our ability to dis-
criminate between CRKP colonization and infection using patient and microbial genomic
features. This approach highlighted the high degree of variation in predictive accuracy
across different facility subsets. Furthermore, despite modest predictive power, we identified
several genomic features consistently associated with infection, indicating that variation in
circulating CRKP strains contributes to infection, even in the context of the critically-ill
patient populations residing in LTACHs. Future work should aim to corroborate our find-
ings with larger cohorts and follow up on strong associations to determine whether they are
indeed risk factors for infection. This could ultimately help identify patients at high risk for
CRKP ST258 infection and devise targeted strategies for infection prevention. Furthermore,
the methods employed here can be used to study ongoing adaptation in other important
MDRO lineages circulating in healthcare facilities.
3.5 Methods
3.5.1 Clinical and genomic data
We used whole-genome sequences of clinical (non-surveillance) CRKP isolates and associ-
ated patient metadata from a prospective observational study performed in 21 LTACHs from
across the U.S. over the course of a year (BioProject accession no. PRJNA415194) [22]. All
isolates were ordered by clinicians as part of clinical care, and clinical practice guidelines
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and policies are standard across sites within the network. We included only the first clinical
bloodstream, respiratory, or urinary isolate from each patient (n=355; Figure 3.S1A), and
subset to only ST258 isolates for the majority of analyses (n=331; Table 3.S1; see supple-
mentary material for reasoning). Patient metadata were obtained from electronic health
records. Core genome variants were identified using a reference genome and accessory genes
were identified using Roary [102]. Details about the clinical data, analysis pipeline [103],
genomic data curation [22, 92, 97, 102, 104, 105, 106, 107], and phylogenetic reconstruction
[66, 68, 72, 73] are provided in the supplementary material. While most clinical data cannot
be shared, the deidentified patient ID, hospital of sample isolation, and isolation site are
included in the Sequence Read Archive metadata for the BioProject.
3.5.2 Outcome definition
Our outcome of interest was colonization vs. clinical infection (Figure 3.S1B). Based on the
U.S. Centers for Disease Control and Prevention’s (CDC) established NHSN surveillance
definitions, we considered all bloodstream isolates as representative of infection, and used
modified definitions as in [46] to classify urinary and respiratory cultures as representative of
infection versus colonization (Table 3.S2) [46, 89]. Any isolate that did not meet the criteria
for infection was classified as colonization. We did not incorporate physician interpretation
in applying the criteria to ensure consistency in applying the definition.
3.5.3 Feature sets
We studied the association between five different feature sets and infection/colonization in
CRKP ST258 (Figure 3.S1C); the feature sets are described below. See supplementary
methods for details on feature set creation and processing. Counts below are for confident
features from the entire dataset prior to subsetting for different analyses.
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1. Patient: Clinical features described in Han et al. (n=50; Table 3.S3) [22].
2. Uncurated genomic: Single nucleotide variants, indels, insertion sequence elements,
and accessory genes (n=2447).
3. Uncurated grouped genomic: Variants grouped into genes (i.e. a burden test, e.g. [91])
and accessory genes (n=3159).
4. Curated genomic: Features identified by Kleborate [92], a tool designed to identify the
presence of various genes and mutations known to be associated with either CRKP
virulence or antibiotic resistance (n=91).
5. Patient & curated genomic: Patient features and curated genomic features (n=141).
3.5.4 Machine learning & model selection
We aimed to classify clinical infection (vs. colonization) using each of the different feature
sets (see above); we built classifiers using the first clinical isolate from each patient for all
isolates, only respiratory isolates, and only urinary isolates. We performed L2 regularized
logistic regression on all feature sets using a modified version of the machine learning pipeline
presented in Topçuoğlu et al. [108] using caret version 6.0-85 [109] in R version 3.6.2 [110]
(Figure 3.S1D1). Furthermore, for the patient and curated genomic feature set we performed
elastic net, random forest, and support vector machine with a radial basis kernel using the
same method but implemented in mikropml version 0.0.2 [111]. We randomly split the data
into 100 unique 80/20 train/test splits, keeping all isolates from each LTACH grouped in
either the training set or the held-out test set to control for facility-level differences among the
isolates (e.g., background of circulating strains within each facility, patient population, and
clinician test ordering frequency). For valid comparison, the train/test splits were identical
across models generated with different feature sets. Hyperparameters were selected via cross-
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validation on the training set to maximize the average AUROC across cross-validation folds.
See supplementary methods for more details.
3.5.5 Model performance
We measured model performance using the median test area under the receiver operating
characteristic curve (AUROC) and area under the precision recall curve (AUPRC), as well
as the interquartile range, across all 100 train/test splits (Figure 3.S1D2).
3.5.6 Features consistently associated with colonization or infec-
tion
To determine the importance of each feature in predicting colonization vs. infection, we
measured how much each feature influenced model performance by calculating feature im-
portance using a permutation test [108] (Figure 3.S1D3). For each combination of feature
and data split, we randomly permuted the feature and calculated the ‘permuted test AU-
ROC’ using the model generated with the training data. Features with a correlation of 1
were permuted together. Other correlation thresholds were tested and the results were very
similar, so we chose to use a correlation of 1 to improve ease of interpretation. We performed
this permutation test 100 times for each feature/data split pair, and obtained a mean feature
importance for each data split. A mean feature importance above zero indicates that that
feature improved model performance for that data split. We highlight features where the
mean permuted test AUROC was above zero in at least 75% of the data splits. In this way,
the permutation importance method allows us to take into account the variation we observe
across the 100 models, which is not possible with standard parametric statistical tests or
odds ratios.
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3.5.7 Insertion sequence identification
We identified insertion sequences in the kfoC gene by running panISa on reads aligned to a
reference genome [107, 66, 112, 113, 64]. See supplementary methods for more details.
3.5.8 Data analysis & visualization
See supplementary material for details on data analysis and visualization in R version 3.6.2





The majority of data elements were obtained from the electronic health record (EHR) which
captures all data in the medical record across clinical sites. This EHR-based electronic
database contains all demographic data, laboratory data (including microbiology), medica-
tion data, and radiographic data. ICD diagnostic and procedure codes were used to ascertain
all coded primary and secondary diagnoses and procedures. The same EHR is used at all
sites and is fully integrated into the EHR-based relational database. We chose not to include
inflammatory markers (e.g. white blood cell count, procalcitonin, etc.) as they are highly
non-specific and add little to designate a culture as representing infection vs. colonization,




We created a snakemake pipeline [103] to perform data pre-processing, machine learning
analysis, and figure generation.
Genomic data
We used Kleborate version 0.3.0 [92] to identify sequence type, capsular types (K locus
[104]) and O locus [105]), virulence factor [97], and antibiotic resistance genes. In ad-
dition, we identified single nucleotide variants (SNVs) and indels by mapping reads to
the KPNIH1 reference genome (BioProject accession number PRJNA73191 [119]; https:
//github.com/Snitkin-Lab-Umich/variant calling pipeline). After variant calling, we iden-
tified the predicted functional impact of variants using SnpEff version 4.3T [106]. We also
identified large insertion sequence (IS) elements using panISa version 0.1.4 with the de-
fault settings [107], and accessory genome genes using Roary version 3.12.0 with the default
settings [102].
Phylogenetic tree reconstruction
We constructed a phylogenetic tree of all ST258 isolates by first creating a whole-genome
alignment by mapping reads to the KPNIH1 reference genome (GenBank accession number
CP008827.1) using bwa mem version 0.7.12 [64]; samtools version 1.9 [66] was used to gener-
ate binary alignment files. We then masked sites identified as recombinant by Gubbins ver-
sion 2.3.2 [68] and used this masked whole-genome alignment to build a maximum likelihood
phylogeny with IQ-TREE version 1.6.12 [72] using a GTR model of nucleotide substitution
and ultra-fast bootstrap with 1000 replicates (-b 1000) [73]. The tree was midpoint-rooted
using the midpoint.root function in phytools version 0.6-99 [75], thus splitting the tree into
ST258 clades I and II [20].
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Phylogenetic clustering test
To determine whether infection isolates cluster on the phylogeny more than expected by
random chance, we performed a permutation test [90]. To identify the true number of isolates
in a pure cluster while controlling for isolate clustering by LTACH, we enumerated isolates
in pure infection or colonization subtrees that also contain isolates from more than one
LTACH. Then we randomized the infection labels across isolates 1000 times and enumerated
the number of isolates in a pure subtree for each randomization. We then compared the
random counts of isolates in a pure cluster to the true number and calculated an empirical
p-value.
Genomic feature set creation
To determine how well machine learning models perform using a targeted vs. untargeted
approach, we performed machine learning with uncurated genomic features as well as curated
genomic features known to be related to virulence. In an attempt to increase power, we
not only performed machine learning on individual uncurated genomic features, but also
using a burden test where genomic variants were grouped into genes and features were
presence/absence of a variant in a gene. This may help capture variation associated with
infection at the gene level that might not be captured at the variant level (e.g. different
samples can have different variants in the same gene that all lead to a similar function).
For the uncurated grouped genomic analysis, grouped variants included SNVs and indels
identified as moderate or high impact by SnpEff and IS elements in a gene or upstream
of a gene. We also grouped modifier variants identified by SnpEff into intergenic regions.
In addition to core genes, we included accessory genes identified by Roary [102] as binary
categorical features in both of the uncurated feature sets.
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Feature set pre-processing
We used five feature sets to study the association between infection and colonization. We
preprocessed all five datasets by mapping categorical features to binary variables, center-
ing and scaling the continuous features (age and length of stay) to a mean of zero and a
variance of one, and removing features present in only one sample or all but one sample.
Some antibiotic features were antibiotic classes, and thus aggregates of other features (e.g.
aminoglycoside, see Table 3.S3). For the uncurated genomic and uncurated grouped genomic
datasets we collapsed genomic features with an identical pattern across all isolates to reduce
machine learning runtime.
Machine learning rationale
We chose to perform L2 regularized logistic regression because it is easily interpretable, often
performs just as well as more complicated methods when limited training data are available
(18), and has a grouping effect, which means that all associated features are identified even
if they are collinear [120]. L2 regularization is equivalent to including a zero-mean Gaus-
sian prior on the weights. Thus, L2 regularized logistic regression includes implicit feature
selection of sparse data by reducing the majority of feature weights to zero. Furthermore,
this method allows us to maintain correlated features in the model, which aids in our inter-
pretation of results as there may be features that together are important for understanding
differences in infection and virulence. Finally, we found that L2 regularized logistic regres-
sion performs as well as other machine learning models for our dataset (Figure 3.S3), and




The machine learning pipeline sets at least 20% of the samples aside for testing in each
train/test split. We split the training data into train and validate sets by LTACH using the
groupKMultiFolds function from the caret R package (caret version 6.0-85) [109]. Within
each training set, we selected hyperparameters via five-fold cross-validation 100 times, max-
imizing the average cross-validation AUROC.
Comparing model performance between feature sets and methods
To determine whether there was a significant difference in model performance between differ-
ent feature sets and different machine learning methods, we calculated a two-sided empirical
p-value for each identical train/test split using the formula 2 x min(fraction of AUROC
differences ≥ 0, fraction of AUROC differences ≤ 0) [121].
Identification of IS element insertions in certain O2v2 kfoC genes
One of the curated genomic features we identified as associated with infection was what
Kleborate called a missing gene (kfoC ) in the O locus operon of certain O2v2 serotypes.
On the Kleborate website, they indicate that a missing gene could represent a truly missing
gene, or a gene that is split between two different contigs. To further investigate this, we
used blastn version 2.9.0 [112] to search for kfoC genes in each of the samples. Additionally,
we aligned the reads of all genomes to CP031810, a complete K. pneumoniae genome from
PATRIC [113] using bwa mem version 0.7.12 [64], and samtools [66] was used to generate
binary alignment files. Next, we used panISa [107] to identify IS element insertions in kfoC.
Data analysis & visualization
We used Fisher’s exact tests for bivariable analyses with categorical variables, and Wilcoxon
rank-sum tests for bivariable analyses with continuous variables. We performed all data
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analysis and visualization in R version 3.6.2 [110] using the following packages: tidyverse
version 1.3.0 [114], cowplot version 1.0.0 [115], ggtree version 2.0.1 [116, 117], ape version
5.3 [118], and phytools version 0.6-99 [75].
3.6.2 Supplementary results
Patients with different sequence types show no substantive differences in infec-
tion status, anatomic site of isolation, or clinical characteristics
Over 90% of the isolates in our dataset were ST258 (Table 3.S2), the dominant strain in
the U.S. [85]. At the level of sequence type, we found no difference in infection preva-
lence (p=0.44) or anatomic site of isolation (p=0.66), indicating that at this coarse level
there was not evidence of differences in strain virulence or adaptation to a certain anatomic
site. Bivariable comparison of patient factors between patients with different sequence
types revealed only four significant differences (unadjusted p-values < 0.05; previous use
of piperacillin/tazobactam, cefepime, ciprofloxacin, or fluoroquinolones). As we found no
substantive differences in infection, anatomic site of isolation, or patient variables when
comparing different sequence types, we chose to focus all subsequent analyses on ST258, the
dominant sequence type in our dataset. The genetic variation of isolates within ST258 is
much smaller than the genetic variation between sequence types, so limiting our analyses to
ST258 could improve our ability to identify associations of interest within ST258.
3.6.3 Supplementary tables and figures




Genomic and Clinical Insights Into the Emergence and Regional
Spread of Colistin-Resistant Klebsiella pneumoniae
4.1 Preamble
This chapter investigates the origins of resistance to the antibiotic colistin in clinical CRKP
isolates. We find that both de novo evolution and onward transmission of resistance are
occurring, and that onward transmission of resistance is particularly rampant in the sub-
lineage identified in Chapter 3. This sublineage is more fit than the other sublineages, and
the fitness cost of colistin resistance in these strains appears to be diminished. The data
preprocessing of variants for this analysis inspired us to create prewas, an R package for
preprocessing data prior to downstream genomic analyses such as genome-wide association
studies (https://github.com/Snitkin-Lab-Umich/prewas).
I performed all of the data analysis and generated all off the figures for this chapter. Other
co-authors performed antibiotic susceptibility testing, variant calling, and phylogenetic tree
reconstruction. This work will be submitted for publication with the following co-authors:
Zena Lapp, Jennifer Han, Divya Choudhary, Stuart Castaneda, Ali Pirani, Ebbing Lauten-
bach, and Evan Snitkin.
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I co-developed the methods for prewas with the other co-first authors. I implemented meth-
ods to find the ancestral allele, generate a binary matrix, and group variants into genes. As
of April 28, 2021 prewas has 3,613 downloads.The manuscript corresponding to prewas was
published in Microbial Genomics in 2020:
Saund K*, Lapp Z*, Thiede SN*, Pirani A, Snitkin ES. Prewas: Data Pre-Processing for
More Informative Bacterial GWAS. Microbial genomics. 2020 May;6(5).
*Indicates co-first author
4.2 Introduction
Multidrug resistant organisms (MDROs) pose a significant threat to public health due to
uncontrolled transmission and dwindling treatment options [1]. Of greatest concern are epi-
demic MDRO lineages that have become adapted to healthcare settings and continually gain
resistance to additional antibiotics that are used to treat them [122, 123]. As resistance evo-
lution continues to outpace our ability to develop new therapies [123], there is a critical need
to improve our understanding of the forces driving the emergence and spread of resistance
so that we can maintain the efficacy of effective antibiotics.
When de novo evolution of antibiotic resistance occurs in an individual, there is often
little to no onward transmission to others due to the fitness cost of resistance in the absence of
antibiotic pressure [124, 17]. However, in some cases this barrier is overcome, as evidenced by
the proliferation of epidemic resistance clones [17, 36]. This may happen when the resistance
variant or gene has an inherently low fitness cost and is thus maintained in the population
even in the absence of antibiotic exposure [125]. Alternatively, the fitness cost of a given
resistance element may depend on the genetic background in which it emerges, leading to
dissemination of these elements only in certain lineages. Indeed, experimental evidence
has shown that the genetic background of a strain interacts with resistance determinants to
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influence the fitness of the resistant strain [126, 127], highlighting the importance of historical
evolutionary events in determining the potential ability of a strain that becomes resistant to
spread. While the preferential spread of resistance elements in specific strains lends support
to the importance of genetic background, in most instances it is unclear what the underlying
epistatic interactions are that lead to these different fitness effects [17]. Deciphering how
the genetic background of a clinical strain influences transmissibility can provide insight into
how fit strain/resistance combinations evolve and disseminate in the healthcare setting.
Carbapenem-resistant Klebsiella pneumoniae (CRKP) is an antibiotic resistance threat
of critical priority as it is resistant to the majority of antibiotics on the market and has high
mortality rates [1]. One of the few remaining treatment options for CRKP is the antibiotic
colistin; however, colistin resistance emerges frequently during treatment with this drug
[128, 129]. Despite the accessibility of these resistance variants to CRKP, their spread to
other patients is rare, with most cases even within a single healthcare setting stemming from
parallel evolution [129]. Here, we document the emergence and spread of multiple resistance
variants in CRKP sequence type (ST) 258 across a regional healthcare network. Through
integration of genomic and clinical data, we show how resistance spread was enhanced in
genetic backgrounds that mitigate the fitness cost of resistance which, when combined with
sustained selective pressure, enabled regional dissemination of colistin resistant lineages.
4.3 Results
4.3.1 Most resistant isolates contain variants in known resistance
genes
Antimicrobial susceptibility testing revealed that 118/337 (35%) CRKP ST258 isolates were
resistant to colistin, and that this resistance was present over the course of our yearlong
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study across diverse long-term acute care hospitals (LTACHs; Figure 4.S1). To identify likely
resistance variants, we first searched all isolates for mcr -containing mobile genetic elements
and variants in canonical chromosomal genes known to confer resistance (pmrA, pmrB, phoP,
phoQ, crrA, crrB, and mgrB). As expected due to the timeframe and locations in which the
isolates were collected (July 2014 to August 2015 in the U.S.) [130], we did not find mcr genes
in any of the isolates. However, the majority of colistin resistance we observed (103/118,
87%) could be explained by resistance variants in canonical resistance genes (Figure 4.S2;
Table 4.S1; see methods for details on identification of resistance variants).
As not all resistance in our dataset could be explained by variants in known resistance
genes, we next performed a genome-wide association study (GWAS) on the isolates with
unknown resistance determinants to identify putative non-canonical resistance-conferring
variants. We identified two additional putative resistance genes in this way: qseC and phos-
photransferase system sugar transporter subunit IIB (Figure 4.S2; Table 4.S1). Resistance
variants in these genes account for 6/15 (40%) of the unknown colistin resistance in our
dataset (see methods for resistance variant identification). Notably, qseC, which explained
resistance in 4 isolates, has been shown to confer colistin resistance in an experimental evo-
lution study using clinical isolates [29]. For all subsequent analyses, we defined resistance
genes as the set of canonical and GWAS-identified resistance genes.
4.3.2 Epistatic interactions appear to influence resistance in iso-
lates with more than one variant in resistance genes
Next, we investigated the relationship between the number of variants in resistance genes
and the level of colistin resistance. While the majority of isolates with one variant in a re-
sistance gene were resistant, surprisingly, the majority of isolates with two or more variants
in resistance genes were susceptible (Figure 4.1A). To better understand how the presence
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of multiple variants in resistance genes influenced the extent of resistance, we explored the
relationship between the number of variants in resistance genes and minimum inhibitory
concentration (MIC). We found that resistant isolates with two variants in resistance genes
tend to have higher MICs on average than those with one (Figure 4.1B). Moreover, suscep-
tible isolates with one variant in a resistance gene have a higher MIC on average than those
with none, suggesting that these variants increased the MIC to a level below the standard
resistance cutoff. In contrast to these cases where resistance variants are associated with
increased MIC, susceptible isolates with two or more variants in resistance genes are more
susceptible on average than those with one or fewer. Furthermore, in most cases where
susceptible isolates harbor multiple variants in resistance genes, at least one of the variants
has been previously shown to confer resistance. These findings suggest that, while variants
in resistance genes often increase MIC as expected, there also exist epistatic interactions
among variants in these genes that influence their impact on resistance phenotypes.
4.3.3 Colistin resistance exhibits patterns of de novo evolution,
onward dissemination, and reversion to susceptibility
To better understand the origin and fate of colistin resistance variants, we investigated
the phylogenetic relationship among colistin resistant and susceptible isolates (Figures 4.2,
4.S3). Visualization of resistance on the phylogeny revealed a striking dichotomy between
a clade II sublineage (defined as clade IIB) and the other ST258 sublineages (clades I and
IIA). Clade IIB contains large clusters of colistin-resistant isolates, while the other two
sublineages largely exhibit sporadic parallel evolution of resistance. Therefore, while 28/118
(24%) isolates acquired colistin resistance from putative de novo resistance evolution events,
two clonal expansions in clade IIB across 11 LTACHs in California (10 in the Los Angeles
area and 1 in San Diego; Figure 4.S4) accounted for over half (69/118, 58%) of resistance
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Figure 4.1: Epistatic interactions appear to influence the extent of colistin resistance in
clinical CRKP isolates.
(A) Most susceptible isolates have no variants in known resistance genes, while most resistant
isolates have at least one variant in a known resistance gene. Many susceptible isolates also
have two variants in known resistance genes, suggesting potential reversion events. The
fractions on the y axis are among all isolates. (B) On average, resistant isolates with two
putative resistance variants have a higher MIC than resistance isolates with one putative
variant, and susceptible isolates with two putative resistance variants have a lower MIC than
susceptible isolates with one putative variant. MIC=minimum inhibitory concentration.
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in this isolate collection. These two clonal expansions were due to a nonsense mutation
in mgrB (Gln30*) and a missense mutation in phoQ (Thr244Asn), respectively. Notably,
these same types of variants occurred in the sporadic colistin resistant isolates (Figure 4.S5),
suggesting that these specific resistance variants were likely not inherently more fit. Within
these clonal expansions, many of the isolates appeared to regain susceptibility to colistin
via the accumulation of additional variants in resistance genes. These putative reversion
mutations usually occurred within the same gene or in a downstream gene of the molecular
pathway to resistance (Figures 4.2, 4.S6), and were sometimes followed by re-acquisition of
resistance through a different mechanism (Figures 4.2, 4.S5).
4.3.4 Resistant strains in clade IIB are more fit than their sus-
ceptible non-revertant counterparts
Next, we were interested in understanding the relative fitness of susceptible, resistant and
revertant isolates in the different sublineages. In particular, we hypothesized that the resis-
tance variants in clade IIB became more widely disseminated due to a decreased associated
fitness cost. To estimate fitness in the context of the healthcare environment we applied an
analytic approach to quantify the epidemic success of isolates in our patient population. In
particular, we took advantage of the comprehensive nature of our sampling and used the
time-scaled haplotypic density (THD) to quantify the extent of relative spread of each geno-
type [131]. Applying the THD metric, we observed significant differences in fitness effects
of resistance variants in clade IIB versus the other clades (Figure 4.3). In clades I and IIA
we observed evidence of a significant fitness cost for resistance variants, as resistant clusters
and susceptible revertants were less fit than susceptible non-revertants from those clades (R
cluster: p = 0.01; S revertant: p = 0.0003). We did not observe a fitness cost for resistant
singletons that did not transmit to others (p = 0.18), which may be because these strains
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Figure 4.2: Distinct resistance evolution patterns exist in different CRKP ST258 sublineages.
Clade IIB exhibits extensive dissemination of resistance variants, as well as several putative
reversion events, while the other clades contain sporadic and less transmitted resistance
variants. Scale bar is in substitutions per site per year. R=resistant; S=susceptible.
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very recently evolved resistance and are thus still closely related to their donor strains. In
contrast, resistance variants in clade IIB were associated with a significant fitness benefit,
with resistant clusters and susceptible revertants from clade IIB being more fit than sus-
ceptible non-revertants from that clade (R cluster: p = 0.03; S revertant: p = 0.02). The
same findings hold when removing isolates from patients who have taken colistin in the past
30 days. Taken together, these findings suggest that resistance variants in isolates from
clade IIB conferred a fitness advantage, which may account for the independent emergence
and spread of two different resistance alleles in this clade. In contrast, the accumulation of
variants in resistance genes in the other clades appears to be associated with a fitness cost,
which is consistent with their limited clonal spread.
Figure 4.3: Colistin resistance does not impart a fitness cost in clade IIB strains.
In clade IIB, resistant clusters are more fit than corresponding susceptible non-revertants. On
the other hand, resistant clusters in other clades are less fit than susceptible non-revertants
in those clades. R=resistant; S=susceptible; THD=time-scaled haplotypic density.
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4.3.5 Isolates with putative de novo resistance, dissemination,
and reversion are each associated with exposure to colistin
in the past 30 days
Lastly, we sought to gain insight into how the use of colistin in the study facilities impacted
the emergence and dissemination of resistance variants. To do this, we investigated the
relationship between different colistin resistance groups and the patient having taken colistin
in the past 30 days. As expected based on previous studies [129], prior exposure to colistin
was positively associated with putative de novo resistance evolution within patients (Figure
4.4). However, we unexpectedly found that prior exposure was also associated with both
resistant clusters and susceptible revertants. This suggests that colistin use may contribute
to the fitness benefit of resistant clusters and susceptible revertents observed in clade IIB in
the THD analysis.
4.4 Discussion
The means by which colistin resistance evolves and disseminates in the healthcare setting
has important implications for antibiotic stewardship and infection control. Here, we used
genomic and clinical data to track the origin and fate of colistin resistance variants across
a comprehensive regional sample of clinical CRKP ST258 isolates. Our analysis identified a
sublineage whose genetic background appears to decrease the fitness cost of resistance, thus
allowing colistin-resistant strains to spread among regional healthcare facilities.
Examination of colistin resistance variants within the comprehensive and longitudinal
context of circulating CRKP strains allowed for inferences into their functional impact and
clinical significance. We discovered that having multiple variants in known resistance genes
appears to increase resistance in resistant isolates, but decrease resistance in susceptible
64
Figure 4.4: Susceptible non-revertants are disenriched in previous exposure to colistin com-
pared to all other groups.
(A) The fraction of patients that had prior exposure to colistin was lower in susceptible non-
revertants compared to all other groups. (B) The odds ratio of previous colistin exposure
is higher for patients with resistant singletons, resistant clusters, and susceptible revertants
when compared to susceptible non-revertants. The 95% confidence intervals of Fisher’s
exact odds ratios (error bars on the plot) were above one for all comparisons. R=resistant;
S=susceptible.
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isolates. Additionally, we identified several instances where a known resistance variant was
present in susceptible isolates, likely due to a suppressor variant in either the same resis-
tance gene or another resistance gene. This finding has two important implications. First,
the presence of a colistin resistance variant cannot necessarily be equated with in vitro phe-
notypic resistance. Clinically, this suggests that testing for resistance variants may not be a
substitute for testing for phenotypic resistance. In fact, while we did observe re-emergence
of resistance in the genetic background of susceptible revertants, revertants may in general
have more difficulty becoming resistant once more, which may lend credence to treating
these patients with colistin [132]. Second, known resistance variants occurring in both resis-
tant and susceptible isolates complicates the computational identification of novel resistance
determinants using GWAS. Possible solutions include increasing sample size or removing
isolates with known resistance variants.
Of particular genomic and clinical interest are two independent instances of emergence
and spread of colistin resistance variants in clade IIB, in stark contrast to the sporadic
emergence of resistance variants in the other clades. Notably, the types of resistance variants
present in clade IIB also occurred in other clades, suggesting that the nature of the variant
itself is not what allowed the clade IIB variants to spread. Instead, our analysis of fitness
using THD suggests that these colistin resistance variants were able to spread in this clade
because the genetic background of the clade reduced the fitness cost of the variants. Colistin
is a cationic polypeptide that binds to the lipid A portion of lipopolysaccharide (LPS) and
displaces divalent cations, thus disrupting the bacterial outer membrane and ultimately
leading to cell death [128]. CRKP becomes resistant to colistin by adding a moiety to lipid
A that increases its charge, thus decreasing colistin’s ability to bind LPS [128]. However,
these moieties may produce a fitness cost due to the changes they likely impart on the
structure of the outer membrane. We previously showed that a defining feature of clade
IIB is that the majority of isolates contain a disruption in the LPS O locus gene kfoC
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[133], a putative glycosyltransferase. Thus, it is possible that inactivation of kfoC facilitates
the spread of colistin resistance by altering the outer membrane in a way that reduces the
fitness cost of resistance-conferring LPS modifications. This possibility has important clinical
implications, as colistin resistance due to this lineage may become more prevalent over time,
thus decreasing the number of patients who can be successfully treated with colistin.
Consistent with exposure to colistin driving the emergence of colistin resistance within
patients, we identified a positive relationship between colistin use in the past 30 days and de
novo resistance evolution. However, we also found a relationship between previous colistin
use and resistant clusters, which may be due to the continued selective pressure to maintain
resistance if colistin is being administered. Thus, although our findings support a reduced
fitness cost of colistin for clade IIB strains, the prevalence of colistin resistance may partially
be driven by colistin use in these facilities. Surprisingly, we also identified an association
between previous colistin use and susceptible revertants. Because of this finding, we hy-
pothesize that there may be a discrepancy between the in vitro MICs and clinical colistin
resistance in the context of the patient [134]. If this is the case, then these additional variants
may in fact be compensatory variants that reduce the fitness cost of resistance, or variants
that alter the strain’s interactions with the surrounding microbial community in such a way
that confers resistance [135]. These findings about the relationship between previous colistin
use and different resistance types highlight the power of using genomic context to investigate
selective pressures imposed on these various groups in the clinic.
One strength of our study is that we have comprehensive sampling of clinical CRKP iso-
lates from LTACHs over the course of a year. This not only allowed us to capture putative
transmission events of colistin resistance, but also allowed us to estimate the fitness of differ-
ent ST258 sublineages. Additionally, whole-genome sequencing of study isolates permitted
us to interrogate not only variants in known resistance genes, but also investigate putative
resistance-conferring variants in other genes using GWAS. Furthermore, our access to clini-
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cal information about previous colistin use allowed us to identify a relationship between this
clinical variable and different types of colistin susceptible and resistant isolates, providing us
with insight into the selective pressures of colistin resistance evolution and spread in patients.
Our study also has several limitations. First, we do not have rectal surveillance cultures,
which limits our ability to fully capture the population of colistin resistant and suscepti-
ble CRKP in the LTACHs studied. While this could bias our clinical collection if certain
strains are more likely to be present and cultured at extraintestinal sites, our findings are
still relevant in that they capture rampant transmission of strains that colonize and infect
these sites. Also, we cannot be certain that our classification of isolates into different cat-
egories of colistin susceptibility and resistance is entirely accurate. For instance, putative
de novo evolution of resistance in resistant singletons may not have occurred in the patient
we sampled. However, our comprehensive sampling of clinical isolates from the facilities in
the study provides some confidence that resistance in resistant singleton isolates did in fact
evolve in that patient. Another limitation of our study is that we do not have information
about colistin exposure prior to 30 days from the isolate collection date, and we do not have
information about the dose or duration of colistin use. Even with this limitation, we were
able to identify significant associations between colistin use and different colistin susceptible
and resistant groups.
In conclusion, we observed distinct dynamics of colistin resistance evolution in different
CRKP ST258 sublineages that appear to be due to differences in the fitness cost of colistin
resistance dependent on the genetic background of the strain. In particular, we identified
an emerging ST258 sublineage that is more fit and more amenable to maintaining colistin
resistance than other ST258 strains. This is of particular concern due to the already limited
treatment options for CRKP, and therefore merits further surveillance to determine the
extent of spread. Furthermore, our findings highlight the importance of surveillance and
monitoring of MDROs for continued evolution and adaptation to the healthcare environment,
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and our method provides a framework for using genomics to study these complex evolutionary
dynamics in clinical isolates.
4.5 Methods
4.5.1 Study isolates and metadata
We used whole-genome sequences of clinical CRKP isolates from a prospective longitudinal
study in 21 U.S. LTACHs over the course of a year (BioProject accession no. PRJNA415194)
[22]. Isolates and metadata were collected, and isolates were sequenced, as described in Han
et al. [22]. Previous patient use of colistin in the past 30 days was extracted from the
electronic health record.
4.5.2 Antibiotic susceptibility testing
To measure colistin resistance, we performed broth microdilution experiments to calculate
the minimum inhibitory concentration (MIC) of each isolate to colistin using a customized
Sensititre plate (MICs tested in µg/mL: 2n where n goes from −2 to 6). To discretize colistin
resistance, we use a cutoff of ≤2 as susceptible, and ≥4 as resistant, as per the Clinical &
Laboratory Standards Institute guidelines. [136].
4.5.3 Isolate selection
Multi-locus sequence types were called using ARIBA [137]. Over 90% of CRKP isolates
collected over the course of the study belonged to ST258; therefore, we focus all of our
analyses on this sequence type. We ordered the isolates by resistance status followed by
collection date. For all analyses except GWAS, only the first patient ST258 isolate from this
ordered list was used, thus prioritizing resistant isolates over susceptible isolates. Sample
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sizes were too small to glean insights into within-host resistance evolution.
4.5.4 Single nucleotide variant calling, indel calling, and phyloge-
netic tree reconstruction
Variant calling was performed with a customized variant calling pipeline (https://github.
com/Snitkin-Lab-Umich/variant calling pipeline) as follows. The quality of sequencing reads
was assessed with FastQC v0.11.9 [62], and Trimmomatic v0.39 [63] was used for trimming
adapter sequences and low-quality bases. Single nucleotide variants (SNVs) were identified
by (i) mapping filtered reads to the ST258 KPNIH1 reference genome (BioProject accession
no. PRJNA73191) using the Burrows-Wheeler short-read aligner (bwa v0.7.17) [64], (ii)
discarding polymerase chain reaction duplicates with Picard v2.24.1 [65], and (iii) calling
variants with SAMtools and bcftools v1.9 [66]. Variants were filtered from raw results using
VariantFiltration from GATK v4.1.9.0 [67] (QUAL > 100; MQ > 50; ≥ 10 reads supporting
variant; and FQ < 0.025). Indels were called using the GATK HaplotypeCaller [138] with
the following filters: root mean square quality (MQ) > 50.0, GATK QualbyDepth (QD) >
2.0, read depth (DP) > 9.0, and allele frequency (AF) > 0.9. In addition, a custom Python
script was used to filter out (mask) variants in the whole-genome alignment that were: (i)
SNVs < 5 base pairs (bp) in proximity to indels, (ii) in a recombinant region identified by
Gubbins v2.3.4 [68], in a phage region identified by the Phaster web tool [139] or (iii) they
resided in tandem repeats of length greater than 20bp as determined using the exact-tandem
program in MUMmer v3.23 [140]. This whole-genome masked variant alignment was used to
reconstruct a maximum likelihood phylogeny with IQ-TREE v1.6.12 [72] using the general
time reversible model GTR+G and ultrafast bootstrap with 1000 replicates (-bb 1000) [73].
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4.5.5 Insertion calling
Large insertions relative to the reference genome were called using panISa v0.1.4 [107].
4.5.6 Variant preprocessing
We preprocessed variants to include multiallelic sites and used the major allele method for
variant binarization, as described in Saund et al. [91]. SnpEff was used to predict the
functional impact of SNVs and indels (high, moderate, low, or modifier) [106]. Additionally,
we considered all insertions in or upstream of genes as high impact, and those downstream
of genes as moderate impact. Low impact variants were excluded from downstream analyses
as they likely do not confer resistance and may induce noise into the analysis.
4.5.7 Identification of putative resistance genes
Known resistance genes
We consider the following genes known (canonical) resistance genes: mgrB, phoP, phoQ,
crrA, crrB, pmrA, and pmrB [141]. We group variants in known resistance genes into the
following categories, in order of decreasing confidence:
1. Known: experimentally confirmed resistance variants, including loss-of-function vari-
ants in mgrB [141, 142, 143, 144].
2. Known site: the variant occurs at a site where there is an experimentally confirmed
resistance variant, but that specific amino acid change has not been experimentally
confirmed [145, 146, 147, 148].
3. Putative: nonsynonymous or disruptive variants in known resistance genes where >60%
of the variants are present in resistant isolates.
We define the set of all of these as resistance variants.
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Genome-wide association study
We performed a burden test using treeWAS v1.0 [149], a convergence-based GWAS method,
as our sample size is relatively small and resistance is a very convergent phenotype. A burden
test increases power to detect resistance genes, and convergence-based methods control for
the structure of the phylogeny more than mixed model methods. For GWAS, we included
only isolates with no mutations in known resistance genes as we were most interested in
identifying novel resistance genes, and because the entire dataset contained a number of
susceptible isolates with known resistance variants that would have confounded the analysis.
We used pyseer v1.3.6 [150] to calculate the number of unique patterns and determine a
p-value cutoff (p < 9.47e-5). Putative resistance genes were considered ones that were
identified as significant by treeWAS, had more than one convergence event on the phylogeny,
and >60% of all the variants in the gene were found in resistant isolates (including isolates
with variants in canonical resistance genes). Variants within these genes were considered
putative resistance variants using the same definition as for known resistance genes. Using
these requirements, we included four putative resistance variants from two putative resistance
genes based on the GWAS results.
4.5.8 Identification of putative suppressor variants
We define putative suppressor variants as those in resistance genes where >60% of isolates
with the variant are susceptible and contain a resistance variant.
4.5.9 Determination of isolate resistance group
We assigned each isolate into one of four categories (Figure 4.S3). Clusters were identified
using the get clusters function in regentrans (https://github.com/Snitkin-Lab-Umich/
regentrans). The four categories are:
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1. Resistant singletons: resistant isolates that do not cluster on the phylogeny, or that
cluster but contain distinct resistance variants.
2. Resistant clusters: resistant isolates that cluster on the phylogeny and contain the same
resistance variant. Additionally, if a cluster on the phylogeny has unknown resistance
variants, we also defined it as a resistant cluster.
3. Susceptible revertants: susceptible isolates that contain a putative resistance-conferring
variant.
4. Susceptible non-revertants: susceptible isolates that do not contain a putative resistance-
conferring variant.
4.5.10 Calculation of time-scaled haplotypic density
We calculated time-scaled haplotypic density (THD) for each isolate with the R package thd
v1.0.1 [131] using the KPNIH1 reference genome length (5,394,056 base pairs), a mutation
rate of 1.03e-6 [21], the time scale parameter, and a timescale of one year. Pairwise single
nucleotide variant distances were calculated with the dist.dna function in ape v5.4.1 [118]
(model = ′N′, pairwise.deletion = TRUE). Significant differences between THD of different
isolates were determined using Wilcox tests.
4.5.11 Calculation of previous colistin use odds ratios




We performed all data visualization in R v4.0.2 [110] using the following packages: tidyverse




Figure 4.S1: Colistin resistance occurred across time and geography.
R=resistant, S=susceptible.
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Figure 4.S2: The majority of colistin resistance can be explained by variants in known
resistance genes.
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Figure 4.S3: Toy example of how resistance groups are defined.
Note that susceptible revertants are defined by the presence of a resistance variant, rather
than a putative suppressor variant. See methods for more details. Heatmap columns are
each a different variant found in a resistance gene. R=resistant, S=susceptible.
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Figure 4.S4: The two clonally expanded resistance variants occur across multiple LTACHs
in California.
10/11 LTACHs in the Los Angeles area have the variant, as well as one LTACH in the San
Diego area.
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Figure 4.S5: Putative resistance and suppressor variants in canonical and non-canonical
resistance genes.
Columns are variants and rows are isolates. All variants except the last panel are from
canonical resistance genes. R=resistant, S=susceptible.
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Figure 4.S6: Schematic of the molecular pathway of canonical colistin resistance genes.
4.6.2 Table
Table 4.S1: Resistance variants.
Gene Variant type Impact Site type Variant Isolate count
mgrB SNV high known Trp47* 1
mgrB SNV high known Lys43* 1
mgrB SNV high known Gln30* 41
mgrB SNV high known Gln22* 1
mgrB SNV high known Lys3* 6
mgrB Indel high known Ile12fs 6
mgrB Indel high known Leu8fs 2
mgrB Insertion high known NA 1
mgrB Insertion high known NA 1
mgrB Insertion high known NA 1
mgrB Insertion high known NA 2
mgrB Insertion high known NA 1
pmrB SNV moderate known Leu82Arg 1
crrB SNV moderate known Gln10Leu 1
crrB SNV moderate known Leu94Met 16
crrB SNV moderate known Pro151Ser 2
crrB SNV moderate known Pro151Ser 1
crrB SNV moderate known Gly183Val 1
mgrB SNV moderate known site Asp31Asn 1
phoQ SNV moderate known site Thr244Asn 85
pmrB SNV moderate known site Pro158Gln 1
pmrA SNV moderate known site Gly53Ser 1
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mgrB SNV moderate putative r Ile41Asn 1
mgrB SNV moderate putative r Asn25Thr 1
mgrB SNV modifier putative r 3
mgrB SNV modifier putative r 3
mgrB SNV modifier putative r 1
mgrB SNV modifier putative r 9
phoP SNV moderate putative r Gly53Val 1
phoQ SNV moderate putative r Leu308Gln 1
phoQ SNV moderate putative r Leu257Gln 4
phoQ SNV moderate putative r Thr248Pro 1
phoQ SNV moderate putative r Leu105Gln 2
phoQ SNV moderate putative r Leu62Pro 2
pmrB SNV moderate putative r Leu262Pro 1
pmrB SNV moderate putative r Ser203Pro 1
crrB SNV moderate putative r Ala200Pro 1
crrB Insertion high putative r NA 1
mgrB SNV moderate putative revert Thr21Pro 1
phoP SNV moderate putative revert Gln202Pro 3
phoP SNV moderate putative revert Thr189Pro 1
phoP SNV moderate putative revert His188Gln 1
phoP SNV moderate putative revert His188Arg 1
phoP SNV moderate putative revert Arg185Leu 3
phoP SNV moderate putative revert Arg111His 11
phoP SNV moderate putative revert Val18Ala 4
phoP Indel high putative revert Thr189fs 1
phoP Indel high putative revert His188fs 1
phoQ SNV moderate putative revert Gln481Leu 1
phoQ SNV moderate putative revert Ala451Thr 1
phoQ SNV moderate putative revert Gly443Ser 1
phoQ SNV moderate putative revert Arg433Leu 13
phoQ SNV moderate putative revert Asp417Val 2
phoQ SNV moderate putative revert Leu322Met 1
phoQ SNV moderate putative revert Glu123Lys 2
phoQ SNV moderate putative revert Ala36Thr 1
phoQ Indel high putative revert Leu344fs 1
phoQ Indel moderate putative revert Thr248 Leu254del 1
crrB Indel high putative revert Ser338fs 16
mgrB SNV moderate other Phe44Cys 1
mgrB SNV moderate other Leu24Pro 3
mgrB SNV moderate other Leu19Gln 1
phoP SNV moderate other Ala80Gly 3
phoQ SNV moderate other Ile462Ser 1
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phoQ SNV moderate other Leu365His 8
phoQ SNV moderate other Pro343Leu 3
phoQ SNV moderate other Thr332Pro 9
phoQ SNV moderate other Arg50Leu 7
phoQ SNV moderate other Gly33Ser 3
phoQ Insertion high other NA 1
pmrB SNV moderate other Pro95Gln 3
pmrB Insertion high other NA 1
PTS sugar transporter SNV moderate gwas r Ser72Ile 1
PTS sugar transporter Insertion high gwas r NA 1
qseC SNV moderate gwas r Val180Ala 9
qseC Indel moderate gwas r Arg12 Leu13del 1
Abbreviations: SNV, single nucleotide variant; PTS; phosphotransferase system; known,
known resistance variant; known r, known site, known resistance variant site; putative r,
putative resistance variant in a known resistance gene; putative revert, putative suppressor




5.1 Major dissertation contributions
This dissertation integrates genomic and clinical data to gain insight into transmission and
adaptation of CRKP in the healthcare environment and provides a framework and corre-
sponding tools for applying the methods developed here to other MDROs. The following
sections summarize the methods, insights, and bioinformatic tools that this dissertation
contributes.
5.1.1 Regional pathogen transmission
Methods
In chapter two, whole-genome sequencing facilitated the investigation of endemic CRKP
ST258 transmission within and between regional healthcare facilities. First, we demonstrate
the utility of using public whole-genome sequences to investigate the extent of importation
into a region. Additionally, our comprehensive sampling of clinical isolates allowed us to
estimate the magnitude of within- and between-facility transmission and compare the extent
of between-facility transmission to patient transfer events. Finally, we combined the results
of our transmission analysis with patient factors to interrogate potential drivers of CRKP
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transmission within healthcare facilities.
Results and implications
We found that, while transmission between facilities is common, within-facility transmission
drives prevalence of CRKP at a given facility. Furthermore, we identified certain patient
factors that may influence the extent of within-facility transmission. These findings have
several implications for public health efforts to reduce CRKP spread in this healthcare net-
work. First, since within-facility transmission drives prevalence, focusing infection control
efforts on reducing intra-facility transmission at high-transmission facilities might reduce
CRKP prevalence more than coordinated efforts between facilities in this region. Second, fu-
ture epidemiological studies can investigate the potential patient risk factors associated with
transmission identified here [154]. Moreover, while these findings about how CRKP spreads
among LTACHs in the Los Angeles area may not be generalizable to other MDROs, regions,
or healthcare settings, the methods applied here can be used to investigate transmission in
other scenarios.
5.1.2 Pathogen evolution and adaptation
Methods
In chapters three and four, genomic analysis provided insight into the continued evolution
and adaptation of CRKP ST258 to the healthcare setting. In chapter three, we demon-
strate the utility of using machine learning to identify pathogen sublineages related to a
certain clinical factor. In chapter four, we integrate phenotypic, phylogenetic, genomic, and
clinical features to gain insight into antibiotic resistance evolution and further probe the
evolutionary dynamics of different ST258 subclades. Furthermore, our comprehensive sam-
pling enabled us to compare fitness differences between resistant and susceptible isolates in
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different sublineages, and corresponding clinical metadata allowed us to gain insight into
additional potential selective pressures related to antibiotic resistance evolution.
Results and implications
We identified an ST258 subclade (clade IIB) present in California LTACHs that appears to
have adapted to the respiratory tract and subsequently evolved increased virulence. Con-
cerningly, clade IIB includes large colistin resistant sublineages that have arisen from clonal
dissemination of resistance, in stark contrast to the sporadic resistance we observe in other
sublineages. Moreover, these clusters of resistant strains seem to be more transmissible than
susceptible non-revertant strains in the subclade, unlike the colistin resistant strains in other
subclades. This finding has important public health implications. First, this emergent and
possibly more virulent sublineage may continue to spread across facilities in the region and
could possibly be exported out of the region. This is particularly concerning as colistin resis-
tance appears to impart less of a fitness cost in clade IIB strains, indicating that this strain
may continue to spread and gain a foothold in the region, after which this antibiotic may
no longer be a viable treatment option for the many patients with these strains. Second,
our identification of an emerging and potentially more transmissible and virulent sublineage
highlights the importance of continued monitoring and surveillance of MDROs using inte-
grated methods such as whole-genome sequencing combined with patient and phenotypic
metadata to identify emerging strains.
5.1.3 Bioinformatic contributions
This dissertation led to the development of three open-source R packages. The regentrans
package implements methods to study within- and between-facility transmission in a regional
network of healthcare facilities and includes several of the methods used in chapter two. The
mikropml package implements the robust machine learning framework used in chapter three
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to make it more accessible for others to use in their own research. The prewas package
implements the method used in chapter four to preprocess bacterial genomic variants from
whole-genome sequencing for downstream analysis. These packages will allow other investi-
gators to apply the methods developed and used here to their own work.
5.2 Future work
The comprehensive dataset used in this dissertation allowed us to investigate many questions
related to CRKP regional transmission and evolution. Future work should aim to build upon
these analyses with additional studies that overcome some of the limitations of the dataset
used here. Limitations of this dataset include that we do not have rectal surveillance cultures,
multiple isolates per patient, longitudinal sampling of patients, or samples from other regional
healthcare facilities. While we were able to glean many insights into CRKP transmission
and adaptation solely using a dataset from LTACHs that includes a single clinical isolate
from each patient included in the study, this additional data would allow us to gain an even
more nuanced understanding of transmission and adaptation within and among patients and
healthcare facilities. The following sections describe future work that could be performed
using this extended dataset, and potential insights gleaned from this work.
5.2.1 Surveillance culturing paired with clinical samples
The vast majority of patients colonized with CRKP remain undetected when using clinical
cultures alone [155, 156, 157]. Performing rectal surveillance culturing of patients in addi-
tion to collecting clinical cultures would allow us to investigate the hidden portion of the
colonization iceberg that is not captured by clinical cultures, as well as differences between
gastrointestinal and extraintestinal isolates.
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Transmission
Collecting surveillance cultures in addition to clinical cultures would allow us to investigate
the full CRKP transmission network. We could probe the connections between patients with
gastrointestinal and extraintestinal colonization (or infection), and compare inferences made
between transmission networks generated with clinical cultures alone to those generated
with surveillance cultures. If most transmission events occur between patients with clinical
cultures, infection control efforts could focus on those patients rather than patients that
are only gastrointestinally colonized. However, if transmission between these two groups of
patients patients is common, surveillance culturing could provide important information for
reducing CRKP transmission.
Evolution and adaptation
Rectal surveillance culturing would also allow us to compare differences in CRKP isolates
from gastrointestinal and extraintestinal colonization. One question of particular interest is
whether clade IIB is enriched in extraintestinal colonization compared to the other clades,
which could indicate that strains from this clade are more likely to migrate from the gas-
trointestinal tract to the respiratory tract, and thus may be more likely to cause infections.
Furthermore, surveillance culturing could provide insight into the extent of undetected col-
istin resistance in CRKP, which may have implications for when and how to use colistin
in the clinic. More generally, consistent surveillance culturing paired with clinical cultures
allows for the early identification of more fit sublineages, potentially yielding insight into
how they arise, and providing the opportunity to attempt to curtail their spread.
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5.2.2 Multiple isolates per patient and longitudinal sampling of
patients
Patients can be multiply colonized with different CRKP strains or sequence types at the
same or multiple body sites, and patients can be colonized for extended periods of time,
leading to variation between strains from the same patient due to within-host evolution
[158]. Additionally, CRKP colonization is a risk factor for future infection [159]. Collection
of multiple isolates per patient at multiple points in time would allow us to investigate
transmission and within-host evolution in more detail.
Transmission
Including only a single isolate from each patient when investigating transmission limits the
resolution of the transmission network if many patients are co-colonized with multiple strains,
either at a single time point or longitudinally. Therefore, having multiple and longitudinal
isolates per patient would allow for a higher resolution analysis of patient-to-patient trans-
mission. Paired with surveillance cultures, this data would allow us to investigate how
incorporating within-host diversity into transmission analyses yields additional insight into
pathways of transmission both within and between healthcare facilities.
Evolution and adaptation
Longitudinal sampling of patients would also allow us to capture within-host evolution. Using
surveillance cultures plus clinical isolates at one or multiple body sites for each patient, we
could investigate genomic and clinical features related to the transition of pathogens from the
gastrointestinal tract to other body sites, and subsequent evolution at those body sites. This
may provide insight into the biological basis of translocation, and predictors of this event.
Of specific interest is the trajectory by which patients become colonized with clade IIB
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isolates in the respiratory tract to further probe the basis of this association. Longitudinal
samples would also allow us to capture within-host evolution of virulence and antibiotic
resistance, providing more direct evidence of genomic and clinical features associated with
these phenotypes. These investigations paired with experimental follow-up studies would
provide valuable insight into pathogen within-host evolution related to adaptation in the
healthcare environment.
5.2.3 Samples from other regional healthcare facilities
There is substantial evidence that LTACHs are hotspots of CRKP transmission [45], and
that interventions in these facilities reduce overall CRKP prevalence across the healthcare
network [49]. For this reason, our analysis focused on transmission and evolution in LTACHs.
However, acquisition of CRKP samples from other facilities in the healthcare network would
allow for a more nuanced understanding of inter-facility transmission dynamics. While we
have strong evidence that patient transfer often drives inter-facility transmission, direct
transfers between LTACHs are rare. In chapter two, we identified paths of maximum patient
flow between LTACHs that usually included at least one intermediate facility, and these paths
correlated well with the extent of transmission between LTACHs. It would be interesting to
determine whether these identified paths of maximum patient flow are the true transmission
paths, and whether there are features of the intermediate facilities, or patients at these
facilities, that drive between-facility transmission. These insights could provide valuable
information for regional infection prevention by highlighting facilities or facility-level factors
that amplify or reduce inter-facility transmission.
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5.2.4 Bioinformatic tools
In this dissertation, we took the approach of developing methods to answer specific questions
of interest, and subsequently creating open-source tools for these methods. This allowed us
to find gaps in the field and build tools to fill those gaps. The future work described above
should continue to follow this framework of developing user-friendly open source methods and
tools for genomic epidemiology. Additionally, these tools must be maintained and potentially
even expanded so that they remain useful to users over time.
5.3 Moving towards real-time genomic epidemiology
While this dissertation acts as a proof-of-principle study for investigating pathogen trans-
mission and adaptation in the healthcare environment, the ultimate goal is to integrate the
methods developed, and insights gained, here and elsewhere into real-time genomic epidemi-
ology in the public health system. This requires a coordinated surveillance and response
framework, increased bioinformatic analysis capacity at public health institutions, and clear
communication of findings between researchers, healthcare workers, and the public.
5.3.1 Building a coordinated surveillance and response framework
As we move from retrospective to real-time analyses, we will need a coordinated surveil-
lance and response framework for practical, yet informative and timely, sample collection,
sequencing, and analysis. This process could be facilitated by a unified healthcare system
that allows for streamlined access to patient clinical data and clinical cultures across regions.
Importantly, this pipeline must include collaboration and communication between clinicians,
epidemiologists, bioinformaticians, microbiologists, and public officials, as well as clear and
timely communication among experts and the community. Lessons learned from this disser-
tation that may be incorporated into this pipeline include the use of clinical cultures from
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LTACHs to investigate regional MDRO transmission, and the utility of clinical cultures for
identifying emerging clones and studying the dynamics of antibiotic resistance evolution.
5.3.2 Increasing bioinformatic analysis capacity at public health
institutions
In this dissertation we developed R packages that, paired with other pre-existing tools, can
be used by those with relatively little coding experience to study pathogen transmission and
adaptation. This is a very small contribution towards the ultimate development and imple-
mentation of tools that people with little to no programming expertise can use to analyze
data. Empowering individuals at local and regional healthcare institutions to perform pre-
liminary analysis of data collected from surveillance systems is key to establishing the ability
to perform local surveillance nationwide. However, collaborations and communication with
bioinformaticians and researchers with more area-specific expertise is also necessary to follow
up on findings that may require more complex analysis, as well as stay up to date on cutting
edge methods and findings. These insights should then be incorporated into public health
standards and policy. The importance of collaborations between public health and research
organizations highlights the interdisciplinary nature of this work, and the importance of clear
communication between these different individuals and entities.
5.4 Conclusion
The work in this dissertation was motivated by the goal of reducing nosocomial transmission,
morbidity, and mortality. Here, we focus on CRKP due to global prevalence, limited treat-
ment options, and high mortality rates. We develop and apply methods to study regional
transmission of endemic MDROs using whole-genome sequencing data and demonstrate that
these tools can provide actionable insights into where transmission is occurring. We also il-
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lustrate the utility of using machine learning for investigating patient outcomes, identify
different patterns of antibiotic resistance evolution in different genomic backgrounds, and
highlight the importance of continual high-resolution monitoring of MDROs for novel po-
tentially high-risk strains. These contributions represent a step in the direction toward our
long-term goal of real-time genomic epidemiology that integrates whole-genome sequenc-
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